



US009433371B2

(12) **United States Patent**
Hafezi et al.

(10) **Patent No.:** **US 9,433,371 B2**
(45) **Date of Patent:** **Sep. 6, 2016**

(54) **IN-BODY DEVICE WITH VIRTUAL DIPOLE SIGNAL AMPLIFICATION**

(71) Applicant: **Proteus Digital Health, Inc.**, Redwood City, CA (US)

(72) Inventors: **Hooman Hafezi**, Redwood City, CA (US); **Benedict Costello**, Piedmont, CA (US); **Timothy Robertson**, Belmont, CA (US); **Maria Casillas Holen**, Santa Clara, CA (US)

(73) Assignee: **Proteus Digital Health, Inc.**, Redwood City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 355 days.

(21) Appl. No.: **14/161,582**

(22) Filed: **Jan. 22, 2014**

(65) **Prior Publication Data**

US 2014/0309504 A1 Oct. 16, 2014

Related U.S. Application Data

(63) Continuation of application No. 12/238,345, filed on Sep. 25, 2008, now Pat. No. 8,961,412.

(60) Provisional application No. 60/975,108, filed on Sep. 25, 2007.

(51) **Int. Cl.**
A61B 5/00 (2006.01)
H01Q 1/00 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61B 5/073** (2013.01); **A61B 5/0002** (2013.01); **A61B 5/0028** (2013.01); **A61B 5/14539** (2013.01); **A61B 5/14546** (2013.01); **H01Q 1/2208** (2013.01); **H01Q 1/273** (2013.01);
(Continued)

(58) **Field of Classification Search**

CPC A61B 5/0073; A61B 2562/16–2562/164;
A61B 5/0002; Y10S 128/902; H01Q 1/27;
H04B 1/02–1/03; H04B 13/005
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,409,721 A 11/1968 Applezweig
3,589,943 A 6/1971 Grubb et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1588649 3/2005
CN 2748032 12/2005

(Continued)

OTHER PUBLICATIONS

Au-Yeung, K., et al., "A Networked System for Self-Management of Drug Therapy and Wellness", Wireless Health '10, Oct. 5-7, 2010, San Diego, 9 pages.

(Continued)

Primary Examiner — Bill Thomson



Assistant Examiner — Marie Archer

(74) *Attorney, Agent, or Firm* — K&L Gates LLP

(57) **ABSTRACT**

Virtual dipole signal amplification for in-body devices, such as implantable and ingestible devices, is provided. Aspects of the in-body deployable antennas of the invention include antennas configured to go from a first configuration to a second configuration following placement in a living body, e.g., via ingestion or implantation. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.

8 Claims, 13 Drawing Sheets



- (51) **Int. Cl.**
H04B 13/00 (2006.01)
A61B 5/07 (2006.01)
A61B 5/145 (2006.01)
H01Q 1/22 (2006.01)
H01Q 1/27 (2006.01)
H01Q 9/16 (2006.01)
- (52) **U.S. Cl.**
CPC **H01Q9/16** (2013.01); **H04B 13/005**
(2013.01); **A61B 2562/02** (2013.01); **A61B**
2562/182 (2013.01); **Y10S 128/902** (2013.01)
- (56) **References Cited**
U.S. PATENT DOCUMENTS
- | | | | | | | | |
|-----------|---|---------|----------------------|-----------|----|---------|-----------------------|
| 3,607,788 | A | 9/1971 | Adolph et al. | 5,079,006 | A | 1/1992 | Urguhart |
| 3,628,669 | A | 12/1971 | McKinnis et al. | 5,167,626 | A | 12/1992 | Casper |
| 3,642,008 | A | 2/1972 | Bolduc | 5,176,626 | A | 1/1993 | Soehendra |
| 3,679,480 | A | 7/1972 | Brown et al. | 5,179,578 | A | 1/1993 | Ishizu |
| 3,682,160 | A | 8/1972 | Murata | 5,245,332 | A | 9/1993 | Katzenstein et al. |
| 3,719,183 | A | 3/1973 | Schwartz | 5,261,402 | A | 11/1993 | DiSabito |
| 3,727,616 | A | 4/1973 | Lenzkes | 5,263,481 | A | 11/1993 | Axelgaard et al. |
| 3,799,802 | A | 3/1974 | Schneble, Jr. et al. | 5,276,710 | A | 1/1994 | Iwasaki |
| 3,828,766 | A | 8/1974 | Krasnow | 5,279,607 | A | 1/1994 | Schentag et al. |
| 3,837,339 | A | 9/1974 | Aisenberg et al. | 5,281,287 | A | 1/1994 | Lloyd |
| 3,893,111 | A | 7/1975 | Cotter | 5,283,136 | A | 2/1994 | Peled et al. |
| 3,944,064 | A | 3/1976 | Bashaw et al. | 5,305,745 | A | 4/1994 | Zacouto |
| 3,967,202 | A | 6/1976 | Batz | 5,318,557 | A | 6/1994 | Gross |
| 3,989,050 | A | 11/1976 | Buchalter | 5,394,882 | A | 3/1995 | Mawhinney |
| 4,017,856 | A | 4/1977 | Wiegand | 5,395,366 | A | 3/1995 | D'Andrea et al. |
| 4,055,178 | A | 10/1977 | Harrigan | 5,412,372 | A | 5/1995 | Parkhurst et al. |
| 4,062,750 | A | 12/1977 | Butler | 5,428,961 | A | 7/1995 | Sakakibara et al. |
| 4,077,397 | A | 3/1978 | Ellis | 5,436,091 | A | 7/1995 | Shackle et al. |
| 4,077,398 | A | 3/1978 | Ellis | 5,443,461 | A | 8/1995 | Atkinson et al. |
| 4,082,087 | A | 4/1978 | Howson | 5,443,843 | A | 8/1995 | Curatolo et al. |
| 4,090,752 | A | 5/1978 | Long | 5,458,141 | A | 10/1995 | Neil et al. |
| 4,106,348 | A | 8/1978 | Auphan | 5,485,841 | A | 1/1996 | Watkin et al. |
| 4,129,125 | A | 12/1978 | Lester | 5,511,548 | A | 4/1996 | Riazzi et al. |
| 4,141,349 | A | 2/1979 | Ory et al. | 5,567,210 | A | 10/1996 | Bates et al. |
| 4,166,453 | A | 9/1979 | McClelland | 5,596,302 | A | 1/1997 | Mastrocola et al. |
| 4,239,046 | A | 12/1980 | Ong | D377,983 | S | 2/1997 | Sabri et al. |
| 4,251,795 | A | 2/1981 | Shibasaki et al. | 5,600,548 | A | 2/1997 | Nguyen et al. |
| 4,269,189 | A | 5/1981 | Abraham | 5,634,466 | A | 6/1997 | Gruner |
| 4,281,664 | A | 8/1981 | Duggan | 5,634,468 | A | 6/1997 | Platt |
| 4,331,654 | A | 5/1982 | Morris | 5,638,406 | A | 6/1997 | Sogabe |
| 4,345,588 | A | 8/1982 | Widder et al. | 5,645,063 | A | 7/1997 | Straka et al. |
| 4,418,697 | A | 12/1983 | Tama | 5,705,189 | A | 1/1998 | Lehmann et al. |
| 4,425,117 | A | 1/1984 | Hugemann | 5,720,771 | A | 2/1998 | Snell |
| 4,439,196 | A | 3/1984 | Higuchi | 5,738,708 | A | 4/1998 | Peachey et al. |
| 4,494,950 | A | 1/1985 | Fischell | 5,740,811 | A | 4/1998 | Hedberg |
| 4,526,474 | A | 7/1985 | Simon | 5,757,326 | A | 5/1998 | Koyama et al. |
| 4,559,950 | A | 12/1985 | Vaughan | 5,792,048 | A | 8/1998 | Schaefer |
| 4,564,363 | A | 1/1986 | Bagnall et al. | 5,802,467 | A | 9/1998 | Salazar |
| 4,578,061 | A | 3/1986 | Lemelson | 5,833,716 | A | 11/1998 | Bar-Or |
| 4,635,641 | A | 1/1987 | Hoffman | 5,836,474 | A | 11/1998 | Wessberg |
| 4,654,165 | A | 3/1987 | Eisenber | 5,845,265 | A | 12/1998 | Woolston |
| 4,663,250 | A | 5/1987 | Ong et al. | 5,862,803 | A | 1/1999 | Besson |
| 4,669,479 | A | 6/1987 | Dunseath | 5,862,808 | A | 1/1999 | Albarelo |
| 4,681,111 | A | 7/1987 | Silvian | 5,868,136 | A | 2/1999 | Fox |
| 4,687,660 | A | 8/1987 | Baker et al. | 5,921,925 | A | 7/1999 | Cartmell et al. |
| 4,725,997 | A | 2/1988 | Urquhart et al. | 5,925,030 | A | 7/1999 | Gross et al. |
| 4,749,575 | A | 6/1988 | Rotman et al. | 5,925,066 | A | 7/1999 | Kroll et al. |
| 4,763,659 | A | 8/1988 | Dunseath | 5,957,854 | A | 9/1999 | Besson et al. |
| 4,767,627 | A | 8/1988 | Caldwell et al. | 5,963,132 | A | 10/1999 | Yoakum et al. |
| 4,784,162 | A | 11/1988 | Ricks | 5,974,124 | A | 10/1999 | Schlueter, Jr. et al. |
| 4,793,825 | A | 12/1988 | Benjamin et al. | 5,981,166 | A | 11/1999 | Mandecki |
| 4,809,705 | A | 3/1989 | Ascher | 5,999,846 | A | 12/1999 | Pardey et al. |
| 4,835,373 | A | 5/1989 | Adams et al. | 6,009,350 | A | 12/1999 | Renken |
| 4,844,076 | A | 7/1989 | Lesho | 6,023,631 | A | 2/2000 | Cartmell et al. |
| 4,871,974 | A | 10/1989 | Davis et al. | 6,038,464 | A | 3/2000 | Axelgaard et al. |
| 4,876,093 | A | 10/1989 | Theeuwes et al. | 6,042,710 | A | 3/2000 | Dubrow |
| 4,896,261 | A | 1/1990 | Nolan | 6,047,203 | A | 4/2000 | Sackner |
| 4,975,230 | A | 12/1990 | Pinkhasov | 6,076,016 | A | 6/2000 | Feierbach et al. |
| 4,987,897 | A | 1/1991 | Funke | 6,081,734 | A | 6/2000 | Batz |
| 5,000,957 | A | 3/1991 | Eckenhoff et al. | 6,083,248 | A | 7/2000 | Thompson |
| 5,016,634 | A | 5/1991 | Vock et al. | 6,090,489 | A | 7/2000 | Hayakawa et al. |
| | | | | 6,091,975 | A | 7/2000 | Daddona et al. |
| | | | | 6,095,985 | A | 8/2000 | Raymond et al. |
| | | | | 6,115,636 | A | 9/2000 | Ryan |
| | | | | 6,117,077 | A | 9/2000 | Del Mar et al. |
| | | | | 6,122,351 | A | 9/2000 | Schlueter, Jr. et al. |
| | | | | 6,141,592 | A | 10/2000 | Pauly |
| | | | | 6,149,940 | A | 11/2000 | Maggi et al. |
| | | | | 6,200,265 | B1 | 3/2001 | Walsh et al. |
| | | | | 6,204,764 | B1 | 3/2001 | Maloney |
| | | | | 6,206,702 | B1 | 3/2001 | Hayden et al. |
| | | | | 6,217,744 | B1 | 4/2001 | Crosby |
| | | | | 6,231,593 | B1 | 5/2001 | Meserol |
| | | | | 6,245,057 | B1 | 6/2001 | Sieben et al. |
| | | | | 6,269,058 | B1 | 7/2001 | Yamanoi et al. |
| | | | | 6,275,476 | B1 | 8/2001 | Wood |
| | | | | 6,285,897 | B1 | 9/2001 | Kilcoyne et al. |
| | | | | 6,287,252 | B1 | 9/2001 | Lugo |
| | | | | 6,288,629 | B1 | 9/2001 | Cofino et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

6,289,238 B1	9/2001	Besson et al.	6,879,810 B2	4/2005	Bouet
6,315,719 B1	11/2001	Rode et al.	6,882,881 B1	4/2005	Lesser et al.
6,342,774 B1	1/2002	Kreisinger et al.	6,897,788 B2	5/2005	Khair et al.
6,344,824 B1	2/2002	Takasugi et al.	6,909,878 B2	6/2005	Haller
6,358,202 B1	3/2002	Arent	6,922,592 B2	7/2005	Thompson et al.
6,364,834 B1	4/2002	Reuss	6,928,370 B2	8/2005	Anuzis et al.
6,366,206 B1	4/2002	Ishikawa et al.	6,929,636 B1	8/2005	Von Alten
6,368,190 B1	4/2002	Easter et al.	6,937,150 B2	8/2005	Medema
6,371,927 B1	4/2002	Brune	6,939,292 B2	9/2005	Mizuno
6,374,670 B1	4/2002	Spelman	6,942,616 B2	9/2005	Kerr
6,380,858 B1	4/2002	Yarin et al.	6,951,536 B2	10/2005	Yokoi
6,390,088 B1	5/2002	Noehl et al.	6,957,107 B2	10/2005	Rogers et al.
6,394,953 B1	5/2002	Devlin et al.	6,959,929 B2	11/2005	Pugnet et al.
6,394,997 B1	5/2002	Lemelson	6,968,153 B1	11/2005	Heinonen et al.
6,409,674 B1	6/2002	Brockway et al.	6,987,965 B2	1/2006	Ng et al.
6,411,567 B1	6/2002	Niemiec et al.	6,990,082 B1	1/2006	Zehavi et al.
6,426,863 B1	7/2002	Munshi	7,002,476 B2	2/2006	Rapchak
6,432,292 B1	8/2002	Pinto et al.	7,004,395 B2	2/2006	Koenck
6,440,069 B1	8/2002	Raymond et al.	7,009,634 B2	3/2006	Iddan et al.
6,441,747 B1	8/2002	Khair	7,009,946 B1	3/2006	Kardach
6,453,199 B1	9/2002	Kobozev	7,013,162 B2	3/2006	Gorsuch
6,477,424 B1	11/2002	Thompson et al.	7,016,648 B2	3/2006	Haller
6,482,156 B2	11/2002	Lliff	7,020,508 B2	3/2006	Stivoric
6,494,829 B1	12/2002	New et al.	7,023,940 B2	4/2006	Nakamura et al.
6,496,705 B1	12/2002	Ng et al.	7,024,248 B2	4/2006	Penner et al.
6,505,077 B1	1/2003	Kast et al.	7,031,745 B2	4/2006	Shen
6,525,996 B1	2/2003	Miyazawa	7,031,857 B2	4/2006	Tarassenko et al.
6,526,315 B1	2/2003	Inagawa	7,039,453 B2	5/2006	Mullick
6,531,026 B1	3/2003	Takeichi et al.	7,044,911 B2	5/2006	Drinan et al.
6,540,699 B1	4/2003	Smith	7,046,649 B2	5/2006	Awater et al.
6,544,174 B2	4/2003	West	7,050,419 B2	5/2006	Azenkot et al.
6,564,079 B1	5/2003	Cory	7,062,308 B1	6/2006	Jackson
6,572,636 B1	6/2003	Hagen et al.	7,076,437 B1	7/2006	Levy
6,574,425 B1	6/2003	Weiss et al.	7,081,693 B2	7/2006	Hamel et al.
6,577,893 B1	6/2003	Besson et al.	7,118,531 B2	10/2006	Krill
6,579,231 B1	6/2003	Phipps	7,125,382 B2	10/2006	Zhou et al.
6,595,929 B2	7/2003	Stivoric	7,127,300 B2	10/2006	Mazar et al.
6,599,284 B2	7/2003	Faour et al.	7,146,228 B2	12/2006	Nielsen
6,605,038 B1	8/2003	Teller	7,146,449 B2	12/2006	Do et al.
6,605,046 B1	8/2003	Del Mar	7,149,581 B2	12/2006	Goedeke et al.
6,609,018 B2	8/2003	Cory	7,154,071 B2	12/2006	Sattler et al.
6,612,984 B1	9/2003	Kerr	7,155,232 B2	12/2006	Godfrey et al.
6,632,175 B1	10/2003	Marshall	7,160,258 B2	1/2007	Imran
6,632,216 B2	10/2003	Houzege et al.	7,161,484 B2	1/2007	Tsoukalis
6,635,279 B2	10/2003	Kolter et al.	7,164,942 B2	1/2007	Avrahami
6,643,541 B2	11/2003	Mok et al.	7,171,166 B2	1/2007	Ng et al.
6,650,718 B1	11/2003	Fujimura et al.	7,171,177 B2	1/2007	Park et al.
6,654,638 B1	11/2003	Sweeney	7,171,259 B2	1/2007	Rytty
6,663,846 B1	12/2003	McCombs	7,176,784 B2	2/2007	Gilbert et al.
6,673,474 B2	1/2004	Yamamoto	7,187,960 B2	3/2007	Abreu
6,680,923 B1	1/2004	Leon	7,188,767 B2	3/2007	Penuela
6,683,493 B1	1/2004	Fujimura et al.	7,194,038 B1	3/2007	Inkinen
6,689,117 B2	2/2004	Sweeney et al.	7,206,630 B1	4/2007	Tarler
6,694,161 B2	2/2004	Mehrotra	7,209,790 B2	4/2007	Thompson et al.
6,704,602 B2	3/2004	Berg et al.	7,215,660 B2	5/2007	Perlman
6,720,923 B1	4/2004	Hayward et al.	7,215,991 B2	5/2007	Besson
6,738,671 B2	5/2004	Christophersom et al.	7,218,967 B2	5/2007	Bergelson
6,740,033 B1	5/2004	Olejniczak et al.	7,231,451 B2	6/2007	Law
6,745,082 B2	6/2004	Axelgaard et al.	7,243,118 B2	7/2007	Lou
6,755,783 B2	6/2004	Cosentino	7,246,521 B2	7/2007	Kim
6,757,523 B2	6/2004	Fry	7,249,212 B2	7/2007	Do
6,759,968 B2	7/2004	Zierolf	7,252,792 B2	8/2007	Perrault
6,771,174 B2	8/2004	Broas	7,253,716 B2	8/2007	Lovoi et al.
6,773,429 B2	8/2004	Sheppard et al.	7,261,690 B2	8/2007	Teller
6,800,060 B2	10/2004	Marshall	7,270,633 B1	9/2007	Goscha
6,801,137 B2	10/2004	Eggers et al.	7,273,454 B2	9/2007	Raymond et al.
6,804,558 B2	10/2004	Haller et al.	7,285,090 B2	10/2007	Stivoric et al.
6,814,706 B2	11/2004	Barton et al.	7,289,855 B2	10/2007	Nghiem
6,822,554 B2	11/2004	Vrijens et al.	7,291,497 B2	11/2007	Holmes
6,836,862 B1	12/2004	Erekson et al.	7,292,139 B2	11/2007	Mazar et al.
6,839,659 B2	1/2005	Tarassenko et al.	7,294,105 B1	11/2007	Islam
6,840,904 B2	1/2005	Goldberg	7,295,877 B2	11/2007	Govari
6,842,636 B2	1/2005	Perrault	7,313,163 B2	12/2007	Liu
6,845,272 B1	1/2005	Thomsen	7,317,378 B2	1/2008	Jarvis et al.
6,864,780 B2	3/2005	Doi	7,318,808 B2	1/2008	Tarassenko et al.
			7,336,732 B1	2/2008	Wiss
			7,336,929 B2	2/2008	Yasuda
			7,342,895 B2	3/2008	Serpa
			7,346,380 B2	3/2008	Axelgaard et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,349,722 B2	3/2008	Witkowski et al.	7,797,033 B2	9/2010	D'Andrea et al.
7,352,998 B2	4/2008	Palin	7,806,852 B1	10/2010	Jursen
7,353,258 B2	4/2008	Washburn	7,809,399 B2	10/2010	Lu
7,357,891 B2	4/2008	Yang et al.	7,844,341 B2	11/2010	Von Arx et al.
7,359,674 B2	4/2008	Markki	7,857,766 B2	12/2010	Lasater et al.
7,366,558 B2	4/2008	Virtanen et al.	7,860,731 B2	12/2010	Jackson et al.
7,366,675 B1	4/2008	Walker et al.	7,899,526 B2	3/2011	Benditt et al.
7,368,190 B2	5/2008	Heller et al.	7,904,133 B2	3/2011	Gehman et al.
7,368,191 B2	5/2008	Andelman et al.	D639,437 S	6/2011	Bishay et al.
7,373,196 B2	5/2008	Ryu et al.	8,025,149 B2	9/2011	Sterry et al.
7,375,739 B2	5/2008	Robbins	8,036,731 B2	10/2011	Kimchy et al.
7,376,435 B2	5/2008	McGowan	8,036,748 B2	10/2011	Zdeblick et al.
7,382,263 B2	6/2008	Danowski et al.	8,060,249 B2	11/2011	Bear et al.
7,387,607 B2	6/2008	Holt	8,073,707 B2	12/2011	Teller et al.
7,388,903 B2	6/2008	Godfrey et al.	8,083,128 B2	12/2011	Dembo et al.
7,389,088 B2	6/2008	Kim	8,123,576 B2	2/2012	Kim
7,392,015 B1	6/2008	Farlow	8,135,596 B2	3/2012	Jung et al.
7,395,106 B2	7/2008	Ryu et al.	8,180,425 B2	5/2012	Selvitelli et al.
7,396,330 B2	7/2008	Banet	8,200,320 B2	6/2012	Kovacs
7,404,968 B2	7/2008	Abrams et al.	8,209,018 B2	6/2012	Osorio et al.
7,413,544 B2	8/2008	Kerr	8,214,007 B2	7/2012	Baker et al.
7,414,534 B1	8/2008	Kroll et al.	8,224,667 B1	7/2012	Miller et al.
7,414,543 B2	8/2008	Rye et al.	8,238,998 B2	8/2012	Park
7,415,242 B1	8/2008	Ngan	8,249,686 B2	8/2012	Libbus et al.
7,419,468 B2	9/2008	Shimizu et al.	8,258,962 B2	9/2012	Robertson et al.
7,424,268 B2	9/2008	Diener	8,262,394 B2	9/2012	Walker et al.
7,424,319 B2	9/2008	Muehlsteff	8,285,356 B2	10/2012	Bly et al.
7,427,266 B2	9/2008	Ayer et al.	8,290,574 B2	10/2012	Feild et al.
7,471,665 B2	12/2008	Perlman	8,301,232 B2	10/2012	Albert et al.
7,485,093 B2	2/2009	Glukhovsky	8,308,640 B2	11/2012	Baldus et al.
7,485,095 B2	2/2009	Shusterman	8,314,619 B2	11/2012	Takiguchi
7,499,674 B2	3/2009	Salokannel et al.	8,315,687 B2	11/2012	Cross et al.
7,502,643 B2	3/2009	Farrington et al.	8,369,936 B2	2/2013	Farrington et al.
7,505,795 B1	3/2009	Lim et al.	8,386,009 B2	2/2013	Lindberg et al.
7,508,248 B2	3/2009	Yoshida	8,389,003 B2	3/2013	Mintchev et al.
7,510,121 B2	3/2009	Koenck	8,404,275 B2	3/2013	Habboushe
7,512,448 B2	3/2009	Malick	8,440,274 B2	5/2013	Wang
7,512,860 B2	3/2009	Miyazaki et al.	8,514,086 B2	8/2013	Harper et al.
7,515,043 B2	4/2009	Welch	8,542,123 B2	9/2013	Robertson
7,519,416 B2	4/2009	Sula et al.	8,564,432 B2	10/2013	Covannon et al.
7,523,756 B2	4/2009	Minai	8,583,227 B2	11/2013	Savage et al.
7,525,426 B2	4/2009	Edelstein	8,597,186 B2	12/2013	Hafezi et al.
7,539,533 B2	5/2009	Tran	8,668,280 B2	3/2014	Heller et al.
7,542,878 B2	6/2009	Nanikashvili	8,718,193 B2	5/2014	Arne et al.
7,551,590 B2	6/2009	Haller	8,722,085 B2	5/2014	McKinney et al.
7,554,452 B2	6/2009	Cole	8,771,183 B2	7/2014	Sloan
7,558,620 B2	7/2009	Ishibashi	8,810,260 B1	8/2014	Zhou
7,558,965 B2	7/2009	Wheeler et al.	8,823,510 B2	9/2014	Downey et al.
7,575,005 B2	8/2009	Mumford	8,836,513 B2	9/2014	Hafezi et al.
7,616,111 B2	11/2009	Covannon	8,868,453 B2	10/2014	Zdeblick
7,616,710 B2	11/2009	Kim et al.	8,932,221 B2	1/2015	Colliou et al.
7,617,001 B2	11/2009	Penner et al.	8,945,005 B2	2/2015	Hafezi et al.
7,639,473 B2	12/2009	Hsu et al.	8,966,973 B1	3/2015	Milone
7,640,802 B2	1/2010	King et al.	9,047,746 B1	6/2015	Euliano et al.
7,647,112 B2	1/2010	Tracey	9,060,708 B2	6/2015	Robertson et al.
7,647,185 B2	1/2010	Tarassenko et al.	9,083,589 B2	7/2015	Arne et al.
7,653,031 B2	1/2010	Godfrey et al.	9,125,868 B2	9/2015	McKinney et al.
7,668,437 B1	2/2010	Yamada et al.	9,198,608 B2	12/2015	Hafezi et al.
7,672,703 B2	3/2010	Yeo et al.	9,235,683 B2	1/2016	Robertson et al.
7,672,714 B2	3/2010	Kuo	9,258,035 B2	2/2016	Robertson et al.
7,673,679 B2	3/2010	Harrison et al.	9,278,177 B2	3/2016	Edwards et al.
7,678,043 B2	3/2010	Gilad	2001/0027331 A1	10/2001	Thompson
7,689,437 B1	3/2010	Teller et al.	2001/0031071 A1	10/2001	Nichols et al.
7,689,833 B2	3/2010	Lange	2001/0044588 A1	11/2001	Mault
7,697,994 B2	4/2010	VanDanacker et al.	2001/0051766 A1	12/2001	Gazdinski
7,712,288 B2	5/2010	Ramasubramanian et al.	2001/0056262 A1	12/2001	Cabiri et al.
7,720,036 B2	5/2010	Sadri	2002/0002326 A1	1/2002	Causey et al.
7,729,776 B2	6/2010	Von Arx et al.	2002/0026111 A1	2/2002	Ackerman
7,733,224 B2	6/2010	Tran	2002/0032384 A1	3/2002	Raymond et al.
7,736,318 B2	6/2010	Costentino	2002/0032385 A1	3/2002	Raymond et al.
7,747,454 B2	6/2010	Bartfeld et al.	2002/0040278 A1	4/2002	Anuzis et al.
7,756,587 B2	7/2010	Penner et al.	2002/0077620 A1	6/2002	Sweeney et al.
7,764,996 B2	7/2010	Zhang et al.	2002/0132226 A1	9/2002	Nair
7,779,614 B1	8/2010	McGonagle et al.	2002/0138009 A1	9/2002	Brockway et al.
7,796,043 B2	9/2010	Euliano et al.	2002/0192159 A1	12/2002	Reitberg
			2002/0193669 A1	12/2002	Glukhovsky
			2002/0193846 A1	12/2002	Pool et al.
			2002/0198470 A1	12/2002	Imran et al.
			2003/0017826 A1	1/2003	Fishman

(56)

References Cited

U.S. PATENT DOCUMENTS

2003/0023150	A1	1/2003	Yokoi et al.	2005/0027205	A1	2/2005	Tarassenko et al.
2003/0028226	A1	2/2003	Thompson	2005/0038321	A1	2/2005	Fujita et al.
2003/0037063	A1	2/2003	Schwartz	2005/0043634	A1	2/2005	Yokoi et al.
2003/0063522	A1	4/2003	Sagar	2005/0043894	A1	2/2005	Fernandez
2003/0065536	A1	4/2003	Hansen	2005/0054897	A1	3/2005	Hashimoto et al.
2003/0076179	A1	4/2003	Branch et al.	2005/0055014	A1	3/2005	Coppeta et al.
2003/0083559	A1	5/2003	Thompson	2005/0062644	A1	3/2005	Leci
2003/0126593	A1	7/2003	Mault	2005/0065407	A1	3/2005	Nakamura et al.
2003/0130714	A1	7/2003	Nielsen et al.	2005/0070778	A1	3/2005	Lackey
2003/0135128	A1	7/2003	Suffin et al.	2005/0075145	A1	4/2005	Dvorak et al.
2003/0135392	A1	7/2003	Vrijens et al.	2005/0090753	A1	4/2005	Goor et al.
2003/0152622	A1	8/2003	Louie-Helm et al.	2005/0092108	A1	5/2005	Andermo
2003/0158466	A1	8/2003	Lynn et al.	2005/0096514	A1	5/2005	Starkebaum
2003/0158756	A1	8/2003	Abramson	2005/0096562	A1	5/2005	Delalic et al.
2003/0162556	A1	8/2003	Libes	2005/0101843	A1	5/2005	Quinn
2003/0164401	A1	9/2003	Andreasson et al.	2005/0101872	A1	5/2005	Sattler
2003/0167000	A1	9/2003	Mullick et al.	2005/0115561	A1	6/2005	Stahmann et al.
2003/0171791	A1	9/2003	KenKnight	2005/0116820	A1	6/2005	Goldreich
2003/0171898	A1	9/2003	Tarassenko et al.	2005/0117389	A1	6/2005	Worledge
2003/0181788	A1	9/2003	Yokoi et al.	2005/0121322	A1	6/2005	Say et al.
2003/0181815	A1	9/2003	Ebner et al.	2005/0131281	A1	6/2005	Ayer et al.
2003/0185286	A1	10/2003	Yuen	2005/0137480	A1	6/2005	Alt et al.
2003/0187337	A1	10/2003	Tarassenko et al.	2005/0143623	A1	6/2005	Kojima
2003/0187338	A1	10/2003	Say et al.	2005/0146594	A1	7/2005	Nakatani et al.
2003/0195403	A1	10/2003	Berner et al.	2005/0148883	A1	7/2005	Boesen
2003/0213495	A1	11/2003	Fujita et al.	2005/0151625	A1	7/2005	Lai
2003/0214579	A1	11/2003	Iddan	2005/0154277	A1	7/2005	Tang et al.
2003/0216622	A1	11/2003	Meron et al.	2005/0154428	A1	7/2005	Bruinsma
2003/0216625	A1	11/2003	Phipps	2005/0156709	A1	7/2005	Gilbert et al.
2003/0216666	A1	11/2003	Ericson et al.	2005/0165323	A1	7/2005	Montgomery
2003/0216729	A1	11/2003	Marchitto	2005/0177069	A1	8/2005	Takizaw
2003/0229382	A1	12/2003	Sun et al.	2005/0182389	A1	8/2005	LaPorte
2003/0232895	A1	12/2003	Omidian et al.	2005/0187789	A1	8/2005	Hatlestad et al.
2004/0008123	A1	1/2004	Carrender et al.	2005/0192489	A1	9/2005	Marshall
2004/0018476	A1	1/2004	LaDue	2005/0197680	A1	9/2005	DelMain et al.
2004/0019172	A1	1/2004	Yang et al.	2005/0228268	A1	10/2005	Cole
2004/0034295	A1	2/2004	Salganicoff	2005/0234307	A1	10/2005	Heinonen
2004/0049245	A1	3/2004	Gass	2005/0240305	A1	10/2005	Bogash et al.
2004/0073095	A1	4/2004	Causey et al.	2005/0245794	A1	11/2005	Dinsmoor
2004/0073454	A1	4/2004	Urquhart et al.	2005/0245839	A1	11/2005	Stivoric et al.
2004/0077995	A1	4/2004	Ferek-Petric	2005/0259768	A1	11/2005	Yang et al.
2004/0082982	A1	4/2004	Gord et al.	2005/0261559	A1	11/2005	Mumford
2004/0087839	A1	5/2004	Raymond et al.	2005/0267556	A1	12/2005	Shuros et al.
2004/0092801	A1	5/2004	Drakulic	2005/0267756	A1	12/2005	Schultz et al.
2004/0106859	A1	6/2004	Say et al.	2005/0277912	A1	12/2005	John
2004/0111011	A1	6/2004	Uchiyama et al.	2005/0277999	A1	12/2005	Strother et al.
2004/0115517	A1	6/2004	Fukuda et al.	2005/0280539	A1	12/2005	Pettus
2004/0121015	A1	6/2004	Chidlaw et al.	2005/0285746	A1	12/2005	Sengupta
2004/0122296	A1	6/2004	Hatlestad	2005/0288594	A1	12/2005	Lewkowicz et al.
2004/0122297	A1	6/2004	Stahmann et al.	2006/0001496	A1	1/2006	Abrosimov et al.
2004/0138558	A1	7/2004	Dunki-Jacobs et al.	2006/0028727	A1	2/2006	Moon et al.
2004/0148140	A1	7/2004	Tarassenko et al.	2006/0036134	A1	2/2006	Tarassenko et al.
2004/0153007	A1	8/2004	Harris	2006/0058602	A1	3/2006	Kwiatkowski et al.
2004/0167226	A1	8/2004	Serafini	2006/0061472	A1	3/2006	Lovoi et al.
2004/0167801	A1	8/2004	Say et al.	2006/0065713	A1	3/2006	Kingery
2004/0171914	A1	9/2004	Avni	2006/0068006	A1	3/2006	Begleiter
2004/0193020	A1	9/2004	Chiba	2006/0074283	A1	4/2006	Henderson
2004/0193029	A1	9/2004	Gluhovsky	2006/0074319	A1	4/2006	Barnes et al.
2004/0193446	A1	9/2004	Mayer et al.	2006/0078765	A1	4/2006	Yang et al.
2004/0199222	A1	10/2004	Sun et al.	2006/0089858	A1	4/2006	Ling
2004/0215084	A1	10/2004	Shimizu et al.	2006/0095091	A1	5/2006	Drew
2004/0218683	A1	11/2004	Batra	2006/0095093	A1	5/2006	Bettesh et al.
2004/0220643	A1	11/2004	Schmidt	2006/0100533	A1	5/2006	Han
2004/0224644	A1	11/2004	Wu	2006/0109058	A1	5/2006	Keating
2004/0225199	A1	11/2004	Evanyk	2006/0110962	A1	5/2006	Powell
2004/0253304	A1	12/2004	Gross et al.	2006/0122474	A1	6/2006	Teller et al.
2004/0258571	A1	12/2004	Lee et al.	2006/0122667	A1	6/2006	Chavan et al.
2004/0260154	A1	12/2004	Sidelnik	2006/0136266	A1	6/2006	Tarassenko et al.
2004/0267240	A1	12/2004	Gross et al.	2006/0142648	A1	6/2006	Banet
2005/0017841	A1	1/2005	Doi	2006/0145876	A1	7/2006	Kimura
2005/0020887	A1	1/2005	Goldberg	2006/0148254	A1	7/2006	McLean
2005/0021103	A1	1/2005	DiLorenzo	2006/0149339	A1	7/2006	Burnes
2005/0021370	A1	1/2005	Riff	2006/0155174	A1	7/2006	Glukhovsky et al.
2005/0021372	A1	1/2005	Mikkelsen	2006/0155183	A1	7/2006	Kroecker
2005/0024198	A1	2/2005	Ward	2006/0158820	A1	7/2006	Takiguchi
				2006/0161225	A1	7/2006	Sormann et al.
				2006/0179949	A1	8/2006	Kim
				2006/0183992	A1	8/2006	Kawashima
				2006/0183993	A1	8/2006	Horn

(56)

References Cited

U.S. PATENT DOCUMENTS

2006/0184092	A1	8/2006	Atanasoska et al.	2008/0014866	A1	1/2008	Lipowshi et al.
2006/0204738	A1	9/2006	Dubrow et al.	2008/0015421	A1	1/2008	Penner
2006/0210626	A1	9/2006	Spaeder	2008/0015494	A1	1/2008	Santini et al.
2006/0216603	A1	9/2006	Choi	2008/0015893	A1	1/2008	Miller et al.
2006/0218011	A1	9/2006	Walker	2008/0020037	A1	1/2008	Robertson et al.
2006/0229053	A1	10/2006	Sivard	2008/0021519	A1	1/2008	DeGeest
2006/0235489	A1	10/2006	Drew	2008/0021521	A1	1/2008	Shah
2006/0243288	A1	11/2006	Kim et al.	2008/0027679	A1	1/2008	Shklarski
2006/0247505	A1	11/2006	Siddiqui	2008/0033273	A1	2/2008	Zhou
2006/0253005	A1	11/2006	Drinan	2008/0033301	A1	2/2008	Dellavecchia et al.
2006/0255064	A1	11/2006	Donaldson	2008/0038588	A1	2/2008	Lee
2006/0265246	A1	11/2006	Hoag	2008/0039700	A1	2/2008	Drinan et al.
2006/0267774	A1	11/2006	Feinberg et al.	2008/0045843	A1	2/2008	Tsuji et al.
2006/0270346	A1	11/2006	Ibrahim	2008/0046038	A1	2/2008	Hill
2006/0273882	A1	12/2006	Posamentier	2008/0051647	A1	2/2008	Wu et al.
2006/0276702	A1	12/2006	McGinnis	2008/0051667	A1	2/2008	Goldreich
2006/0280227	A1	12/2006	Pinkney	2008/0051767	A1	2/2008	Rossing et al.
2006/0282001	A1	12/2006	Noel	2008/0058614	A1	3/2008	Banet
2006/0285607	A1	12/2006	Strodtbeck et al.	2008/0062856	A1	3/2008	Feher
2006/0287693	A1	12/2006	Kraft et al.	2008/0065168	A1	3/2008	Bitton et al.
2006/0289640	A1	12/2006	Mercure	2008/0074307	A1	3/2008	Boric-Lubecke
2006/0293607	A1	12/2006	Alt	2008/0077015	A1	3/2008	Boric-Lubecke
2007/0000776	A1	1/2007	Karube et al.	2008/0077028	A1	3/2008	Schaldach et al.
2007/0002038	A1	1/2007	Suzuki	2008/0077188	A1	3/2008	Denker et al.
2007/0006636	A1	1/2007	King et al.	2008/0077430	A1	3/2008	Singer et al.
2007/0008113	A1	1/2007	Spoonhower et al.	2008/0091089	A1	4/2008	Guillory et al.
2007/0016089	A1	1/2007	Fischell et al.	2008/0091114	A1	4/2008	Min
2007/0027386	A1	2/2007	Such	2008/0097549	A1	4/2008	Colbaugh
2007/0027388	A1	2/2007	Chou	2008/0097917	A1	4/2008	Dicks
2007/0038054	A1	2/2007	Zhou	2008/0099366	A1	5/2008	Niemic et al.
2007/0049339	A1	3/2007	Barak et al.	2008/0103440	A1	5/2008	Ferren et al.
2007/0055098	A1	3/2007	Shimizu et al.	2008/0112885	A1	5/2008	Okunev et al.
2007/0060797	A1	3/2007	Ball	2008/0114224	A1	5/2008	Bandy et al.
2007/0060800	A1	3/2007	Drinan et al.	2008/0119705	A1	5/2008	Patel
2007/0066929	A1	3/2007	Ferren et al.	2008/0119716	A1	5/2008	Boric-Lubecke
2007/0073353	A1	3/2007	Rooney et al.	2008/0121825	A1	5/2008	Trovato et al.
2007/0088194	A1	4/2007	Tahar	2008/0137566	A1	6/2008	Marholev
2007/0096765	A1	5/2007	Kagan	2008/0139907	A1	6/2008	Rao et al.
2007/0106346	A1	5/2007	Bergelson	2008/0140403	A1	6/2008	Hughes et al.
2007/0123772	A1	5/2007	Euliano	2008/0146871	A1	6/2008	Arneson et al.
2007/0129622	A1	6/2007	Bourget	2008/0146889	A1	6/2008	Young
2007/0130287	A1	6/2007	Kumar	2008/0146892	A1	6/2008	LeBeouf
2007/0135691	A1	6/2007	Zingewicz et al.	2008/0154104	A1	6/2008	Lamego
2007/0135803	A1	6/2007	Belson	2008/0166992	A1	7/2008	Ricordi
2007/0142721	A1	6/2007	Berner et al.	2008/0175898	A1	7/2008	Jones et al.
2007/0156016	A1	7/2007	Betesh	2008/0183245	A1	7/2008	Van Oort
2007/0160789	A1	7/2007	Merical	2008/0188837	A1	8/2008	Belsky et al.
2007/0162089	A1	7/2007	Mosesov	2008/0194912	A1	8/2008	Trovato et al.
2007/0162090	A1	7/2007	Penner	2008/0208009	A1	8/2008	Shklarski
2007/0167495	A1	7/2007	Brown et al.	2008/0214901	A1	9/2008	Gehman
2007/0167848	A1	7/2007	Kuo et al.	2008/0214903	A1	9/2008	Orbach
2007/0173701	A1	7/2007	Al-Ali	2008/0214985	A1	9/2008	Yanaki
2007/0179347	A1	8/2007	Tarassenko et al.	2008/0223936	A1	9/2008	Mickle et al.
2007/0179371	A1	8/2007	Peyser et al.	2008/0243020	A1	10/2008	Chou
2007/0180047	A1	8/2007	Dong et al.	2008/0249360	A1	10/2008	Li
2007/0185393	A1	8/2007	Zhou	2008/0262320	A1	10/2008	Schaefer et al.
2007/0191002	A1	8/2007	Ge	2008/0262336	A1	10/2008	Ryu
2007/0196456	A1	8/2007	Stevens	2008/0269664	A1	10/2008	Trovato et al.
2007/0207793	A1	9/2007	Myer	2008/0275312	A1	11/2008	Mosesov
2007/0207858	A1	9/2007	Breving	2008/0281636	A1	11/2008	Jung et al.
2007/0208233	A1	9/2007	Kovacs	2008/0284599	A1	11/2008	Zdeblick et al.
2007/0213659	A1	9/2007	Trovato et al.	2008/0288026	A1	11/2008	Cross et al.
2007/0237719	A1	10/2007	Jones	2008/0288027	A1	11/2008	Kroll
2007/0244370	A1	10/2007	Kuo et al.	2008/0294020	A1	11/2008	Sapounas
2007/0244810	A1	10/2007	Rudolph	2008/0299197	A1	12/2008	Toneguzzo et al.
2007/0249946	A1	10/2007	Kumar et al.	2008/0300572	A1	12/2008	Rankers
2007/0255198	A1	11/2007	Leong et al.	2008/0303638	A1	12/2008	Nguyen
2007/0255330	A1	11/2007	Lee	2008/0303665	A1	12/2008	Naik et al.
2007/0270672	A1	11/2007	Hayter	2008/0306357	A1	12/2008	Korman
2007/0279217	A1	12/2007	Venkatraman	2008/0306359	A1	12/2008	Zdeblick et al.
2007/0282174	A1	12/2007	Sabatino	2008/0306360	A1	12/2008	Robertson et al.
2007/0282177	A1	12/2007	Pilz	2008/0306362	A1	12/2008	Davis
2007/0291715	A1	12/2007	Laroia et al.	2008/0311852	A1	12/2008	Hansen
2007/0299480	A1	12/2007	Hill	2008/0312522	A1	12/2008	Rowlandson
2008/0004503	A1	1/2008	Nisani et al.	2008/0316020	A1	12/2008	Robertson
				2009/0006133	A1	1/2009	Weinert
				2009/0009330	A1	1/2009	Sakama et al.
				2009/0009332	A1	1/2009	Nunez et al.
				2009/0024045	A1	1/2009	Prakash

(56)

References Cited

U.S. PATENT DOCUMENTS

2009/0024112	A1	1/2009	Edwards et al.	2009/0192379	A1	7/2009	Say et al.
2009/0030293	A1	1/2009	Cooper et al.	2009/0198115	A1	8/2009	Say et al.
2009/0030297	A1	1/2009	Miller	2009/0198116	A1	8/2009	Say et al.
2009/0034209	A1	2/2009	Joo	2009/0198175	A1	8/2009	Say et al.
2009/0043171	A1	2/2009	Rule	2009/0203964	A1	8/2009	Shimizu et al.
2009/0048498	A1	2/2009	Riskey	2009/0203971	A1	8/2009	Sciarappa
2009/0062634	A1	3/2009	Say et al.	2009/0203972	A1	8/2009	Heneghan
2009/0062670	A1	3/2009	Sterling	2009/0203978	A1	8/2009	Say et al.
2009/0069642	A1	3/2009	Gao	2009/0204265	A1	8/2009	Hackett
2009/0069655	A1	3/2009	Say et al.	2009/0210164	A1	8/2009	Say et al.
2009/0069656	A1	3/2009	Say et al.	2009/0216101	A1	8/2009	Say et al.
2009/0069657	A1	3/2009	Say et al.	2009/0216102	A1	8/2009	Say et al.
2009/0069658	A1	3/2009	Say et al.	2009/0227204	A1	9/2009	Robertson et al.
2009/0076340	A1	3/2009	Libbus et al.	2009/0227876	A1	9/2009	Tran
2009/0076343	A1	3/2009	James	2009/0227940	A1	9/2009	Say et al.
2009/0076397	A1	3/2009	Libbus et al.	2009/0227941	A1	9/2009	Say et al.
2009/0082645	A1	3/2009	Hafezi et al.	2009/0227988	A1	9/2009	Wood et al.
2009/0087483	A1	4/2009	Sison	2009/0228214	A1	9/2009	Say et al.
2009/0088618	A1	4/2009	Arneson	2009/0231125	A1	9/2009	Baldus
2009/0099435	A1	4/2009	Say et al.	2009/0234200	A1	9/2009	Husheer
2009/0105561	A1	4/2009	Boyden et al.	2009/0243833	A1	10/2009	Huang
2009/0110148	A1	4/2009	Zhang	2009/0247836	A1	10/2009	Cole et al.
2009/0112626	A1	4/2009	Talbot	2009/0253960	A1	10/2009	Takenaka et al.
2009/0124871	A1	5/2009	Arshak	2009/0256702	A1	10/2009	Robertson
2009/0131774	A1	5/2009	Sweitzer	2009/0264714	A1	10/2009	Chou
2009/0134181	A1	5/2009	Wachman et al.	2009/0264964	A1	10/2009	Abrahamson
2009/0135886	A1	5/2009	Robertson et al.	2009/0265186	A1	10/2009	Tarassenko et al.
2009/0142853	A1	6/2009	Warrington et al.	2009/0273467	A1	11/2009	Elixmann
2009/0149839	A1	6/2009	Hyde et al.	2009/0277815	A1	11/2009	Kohl et al.
2009/0157113	A1	6/2009	Marcotte	2009/0281539	A1	11/2009	Selig
2009/0157358	A1	6/2009	Kim	2009/0292194	A1	11/2009	Libbus et al.
2009/0161602	A1	6/2009	Matsumoto	2009/0295548	A1	12/2009	Ronkka
2009/0163789	A1	6/2009	Say et al.	2009/0296677	A1	12/2009	Mahany
2009/0171180	A1	7/2009	Pering	2009/0301925	A1	12/2009	Alloro et al.
2009/0173628	A1	7/2009	Say et al.	2009/0303920	A1	12/2009	Mahany
2009/0177055	A1	7/2009	Say et al.	2009/0306633	A1	12/2009	Trovato et al.
2009/0177056	A1	7/2009	Say et al.	2009/0312619	A1	12/2009	Say et al.
2009/0177057	A1	7/2009	Say et al.	2009/0318303	A1	12/2009	Delamarche et al.
2009/0177058	A1	7/2009	Say et al.	2009/0318761	A1	12/2009	Rabinovitz
2009/0177059	A1	7/2009	Say et al.	2009/0318779	A1	12/2009	Tran
2009/0177060	A1	7/2009	Say et al.	2009/0318783	A1	12/2009	Rohde
2009/0177061	A1	7/2009	Say et al.	2009/0318793	A1	12/2009	Datta
2009/0177062	A1	7/2009	Say et al.	2010/0001841	A1	1/2010	Cardullo
2009/0177063	A1	7/2009	Say et al.	2010/0006585	A1	1/2010	Flowers et al.
2009/0177064	A1	7/2009	Say et al.	2010/0010330	A1	1/2010	Rankers
2009/0177065	A1	7/2009	Say et al.	2010/0033324	A1	2/2010	Shimizu et al.
2009/0177066	A1	7/2009	Say et al.	2010/0049004	A1	2/2010	Edman et al.
2009/0182206	A1	7/2009	Najafi	2010/0049006	A1	2/2010	Magar
2009/0182207	A1	7/2009	Riskey et al.	2010/0049012	A1	2/2010	Dijkman et al.
2009/0182212	A1	7/2009	Say et al.	2010/0049069	A1	2/2010	Tarassenko et al.
2009/0182213	A1	7/2009	Say et al.	2010/0056878	A1	3/2010	Partin
2009/0182214	A1	7/2009	Say et al.	2010/0056891	A1	3/2010	Say et al.
2009/0182215	A1	7/2009	Say et al.	2010/0056939	A1	3/2010	Tarassenko et al.
2009/0182388	A1	7/2009	Von Arx	2010/0057041	A1	3/2010	Hayter
2009/0187088	A1	7/2009	Say et al.	2010/0062709	A1	3/2010	Kato
2009/0187089	A1	7/2009	Say et al.	2010/0063438	A1	3/2010	Bengtsson
2009/0187090	A1	7/2009	Say et al.	2010/0063841	A1	3/2010	D'Ambrosia et al.
2009/0187091	A1	7/2009	Say et al.	2010/0069002	A1	3/2010	Rong
2009/0187092	A1	7/2009	Say et al.	2010/0069717	A1	3/2010	Hafezi et al.
2009/0187093	A1	7/2009	Say et al.	2010/0081894	A1	4/2010	Zdeblick et al.
2009/0187094	A1	7/2009	Say et al.	2010/0082367	A1	4/2010	Hains et al.
2009/0187095	A1	7/2009	Say et al.	2010/0099967	A1	4/2010	Say et al.
2009/0187381	A1	7/2009	King et al.	2010/0099968	A1	4/2010	Say et al.
2009/0192351	A1	7/2009	Nishino	2010/0099969	A1	4/2010	Say et al.
2009/0192368	A1	7/2009	Say et al.	2010/0100077	A1	4/2010	Rush
2009/0192369	A1	7/2009	Say et al.	2010/0100078	A1	4/2010	Say et al.
2009/0192370	A1	7/2009	Say et al.	2010/0100237	A1	4/2010	Ratnakar
2009/0192371	A1	7/2009	Say et al.	2010/0106001	A1	4/2010	Say et al.
2009/0192372	A1	7/2009	Say et al.	2010/0118853	A1	5/2010	Godfrey
2009/0192373	A1	7/2009	Say et al.	2010/0131434	A1	5/2010	Magent et al.
2009/0192374	A1	7/2009	Say et al.	2010/0139672	A1	6/2010	Kroll et al.
2009/0192375	A1	7/2009	Say et al.	2010/0160742	A1	6/2010	Seidl et al.
2009/0192376	A1	7/2009	Say et al.	2010/0168659	A1	7/2010	Say et al.
2009/0192377	A1	7/2009	Say et al.	2010/0179398	A1	7/2010	Say et al.
2009/0192378	A1	7/2009	Say et al.	2010/0185055	A1	7/2010	Robertson
				2010/0191073	A1	7/2010	Tarassenko et al.
				2010/0203394	A1	8/2010	Bae et al.
				2010/0210299	A1	8/2010	Gorbachov
				2010/0217100	A1	8/2010	LeBoeuf et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2010/0222652 A1 9/2010 Cho
 2010/0228113 A1 9/2010 Solosko
 2010/0233026 A1 9/2010 Ismagliov et al.
 2010/0234706 A1 9/2010 Gilland
 2010/0234715 A1 9/2010 Shin
 2010/0234914 A1 9/2010 Shen
 2010/0245091 A1 9/2010 Singh
 2010/0249881 A1 9/2010 Corndorf
 2010/0256461 A1 10/2010 Mohamedali
 2010/0259543 A1 10/2010 Tarassenko et al.
 2010/0268048 A1 10/2010 Say et al.
 2010/0268049 A1 10/2010 Say et al.
 2010/0268050 A1 10/2010 Say et al.
 2010/0268288 A1 10/2010 Hunter et al.
 2010/0274111 A1 10/2010 Say et al.
 2010/0280345 A1 11/2010 Say et al.
 2010/0280346 A1 11/2010 Say et al.
 2010/0295694 A1 11/2010 Kauffman et al.
 2010/0298668 A1 11/2010 Hafezi et al.
 2010/0298730 A1 11/2010 Tarassenko et al.
 2010/0299155 A1 11/2010 Findlay et al.
 2010/0312188 A1 12/2010 Robertson et al.
 2010/0312577 A1 12/2010 Goodnow et al.
 2010/0312580 A1 12/2010 Tarassenko et al.
 2010/0332443 A1 12/2010 Gartenberg
 2011/0004079 A1 1/2011 Al Ali et al.
 2011/0009715 A1 1/2011 O'Reilly et al.
 2011/0029622 A1 2/2011 Walker et al.
 2011/0040203 A1 2/2011 Savage et al.
 2011/0050431 A1 3/2011 Hood et al.
 2011/0054265 A1 3/2011 Hafezi et al.
 2011/0065983 A1 3/2011 Hafezi et al.
 2011/0077660 A1 3/2011 Janik et al.
 2011/0081860 A1 4/2011 Brown et al.
 2011/0105864 A1 5/2011 Robertson et al.
 2011/0112686 A1 5/2011 Nolan et al.
 2011/0124983 A1 5/2011 Kroll et al.
 2011/0144470 A1 6/2011 Mazar et al.
 2011/0224912 A1 9/2011 Bhavaraju et al.
 2011/0230732 A1 9/2011 Edman et al.
 2011/0237924 A1 9/2011 McGusty et al.
 2011/0270112 A1 11/2011 Manera et al.
 2011/0279963 A1 11/2011 Kumar et al.
 2012/0024889 A1 2/2012 Robertson et al.
 2012/0029309 A1 2/2012 Paquet et al.
 2012/0062371 A1 3/2012 Radivojevic et al.
 2012/0083715 A1 4/2012 Yuen et al.
 2012/0089000 A1 4/2012 Bishay et al.
 2012/0101396 A1 4/2012 Solosko et al.
 2012/0116184 A1 5/2012 Shieh
 2012/0197144 A1 8/2012 Christ et al.
 2012/0214140 A1 8/2012 Brynson et al.
 2012/0265544 A1 10/2012 Hwang et al.
 2012/0299723 A1 11/2012 Hafezi et al.
 2012/0310070 A1 12/2012 Kumar et al.
 2012/0316413 A1 12/2012 Liu et al.
 2013/0030259 A1 1/2013 Thomsen et al.
 2013/0057385 A1 3/2013 Murakami et al.
 2013/0060115 A1 3/2013 Gehman et al.
 2014/0039445 A1 2/2014 Austin et al.
 2014/0315170 A1 10/2014 Ionescu et al.
 2015/0051465 A1 2/2015 Robertson et al.
 2015/0080677 A1 3/2015 Thompson et al.
 2015/0080678 A1 3/2015 Frank et al.
 2015/0080679 A1 3/2015 Frank et al.
 2015/0080680 A1 3/2015 Zdeblick et al.
 2015/0080681 A1 3/2015 Hafezi et al.
 2015/0127737 A1 5/2015 Thompson et al.
 2015/0127738 A1 5/2015 Thompson et al.
 2015/0149375 A1 5/2015 Thompson et al.
 2015/0165313 A1 6/2015 Thompson et al.
 2015/0171924 A1 6/2015 Zdeblick
 2015/0182463 A1 7/2015 Hafezi et al.
 2015/0193593 A1 7/2015 Zdeblick et al.

2015/0230728 A1 8/2015 Hafezi et al.
 2015/0365115 A1 12/2015 Arne et al.
 2016/0106339 A1 4/2016 Behzadi et al.

FOREIGN PATENT DOCUMENTS

CN 1991868 7/2007
 CN 101005470 7/2007
 CN 201076456 6/2008
 DE 10313005 10/2004
 EP 0344939 12/1989
 EP 1246356 10/2002
 EP 1342447 9/2003
 EP 1534054 5/2005
 EP 1702553 9/2006
 EP 1789128 5/2007
 EP 2143369 1/2010
 GB 775071 5/1957
 GB 2432862 6/2007
 IL 172917 6/2010
 JP 61017949 1/1986
 JP S63280393 11/1988
 JP 05-228128 9/1993
 JP 09330159 12/1997
 JP 10-14898 1/1998
 JP 2000-506410 5/2000
 JP 2002-224053 8/2002
 JP 2002263185 9/2002
 JP 2002282219 10/2002
 JP 2002291684 10/2002
 JP 3454525 10/2003
 JP 2004-7187 1/2004
 JP 2004507188 3/2004
 JP 2004-134384 4/2004
 JP 2004-313242 11/2004
 JP 2004318534 11/2004
 JP 2005-073886 3/2005
 JP 2005-304880 4/2005
 JP 2005124708 5/2005
 JP 2005148021 6/2005
 JP 2005-532841 11/2005
 JP 2005-532849 11/2005
 JP 2005343515 12/2005
 JP 2006006377 1/2006
 JP 2006509574 3/2006
 JP 2006-177699 7/2006
 JP 2006187611 7/2006
 JP 2006278091 10/2006
 JP 2006346000 12/2006
 JP 3876573 1/2007
 JP 2007159631 6/2007
 JP 2007-313340 12/2007
 JP 2007330677 12/2007
 JP 2008011865 1/2008
 JP 2008501415 1/2008
 JP 2008191955 8/2008
 JP 2008289724 12/2008
 JP 2009-061236 3/2009
 KR 20020015907 3/2002
 KR 20020061744 7/2002
 KR 200609977523 7/2006
 KR 927471 11/2009
 KR 20110137001 12/2011
 KR 10-2012-099995 9/2012
 TW 200301864 7/2003
 TW 553735 9/2003
 TW 200724094 7/2007
 WO 8802237 4/1988
 WO 9221307 12/1992
 WO 9308734 5/1993
 WO 9319667 10/1993
 WO 9401165 1/1994
 WO 9516393 6/1995
 WO 9714112 4/1997
 WO 9739963 10/1997
 WO 9843537 10/1998
 WO 9937290 7/1999
 WO 9959465 11/1999
 WO 0033246 6/2000

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	WO 0100085	1/2001	WO	WO2007127879	11/2007
WO	WO 0147466	7/2001	WO	WO2007127945	11/2007
WO	WO 0149364	7/2001	WO	WO2007128165	11/2007
WO	WO 0174011	10/2001	WO	WO2007130491	11/2007
WO	WO 0180731	11/2001	WO	WO2007133526	11/2007
WO	WO0235997	5/2002	WO	WO2007143535	12/2007
WO	WO 02045489	6/2002	WO	WO2007149546	12/2007
WO	WO 02058330	7/2002	WO	WO2006104843	1/2008
WO	WO 02062276	8/2002	WO	WO2008008281	1/2008
WO	WO 02087681	11/2002	WO	WO2008012700	1/2008
WO	WO 02095351	11/2002	WO	WO2008030482	3/2008
WO	WO 03005877	1/2003	WO	WO2008039030	4/2008
WO	WO 03050643	6/2003	WO	WO2008052136	5/2008
WO	WO 03068061	8/2003	WO	WO2008061138	5/2008
WO	WO 2004014225	2/2004	WO	WO2008063626	5/2008
WO	WO 2004019172	3/2004	WO	WO2008066617	6/2008
WO	WO 2004039256	5/2004	WO	WO2008076464	6/2008
WO	WO 2004059551	7/2004	WO	WO2008089232	7/2008
WO	WO 2004066833	8/2004	WO	WO2008091683	7/2008
WO	WO 2004066834	8/2004	WO	WO2008095183	8/2008
WO	WO 2004066903	8/2004	WO	WO2008097652	8/2008
WO	WO 2004068748	8/2004	WO	WO2008101107	8/2008
WO	WO 2004068881	8/2004	WO	WO2008112577	9/2008
WO	WO 2004075751	9/2004	WO	WO2008112578	9/2008
WO	WO 2004109316	12/2004	WO	WO2008120156	10/2008
WO	WO2004110555	12/2004	WO	WO2008133394	11/2008
WO	WO 2005011237	2/2005	WO	WO2008134185	11/2008
WO	WO 2005020023	3/2005	WO	WO2008150633	12/2008
WO	WO 2005024687	3/2005	WO	WO2009001108	12/2008
WO	WO 2005041767	5/2005	WO	WO2009005759	1/2009
WO	WO 2005047837	5/2005	WO	WO2009006615	1/2009
WO	WO 2005051166	6/2005	WO	WO2009022343	2/2009
WO	WO 2005053517	6/2005	WO	WO2009029453	3/2009
WO	WO2005069887	8/2005	WO	WO2009032381	3/2009
WO	WO 2005082436	9/2005	WO	WO2009036334	3/2009
WO	WO 2005083621	9/2005	WO	WO2009051829	4/2009
WO	WO 2005110238	11/2005	WO	WO2009051830	4/2009
WO	WO2005117697	12/2005	WO	WO2009063377	5/2009
WO	WO2006009404	1/2006	WO	WO2009081348	7/2009
WO	WO2006016370	2/2006	WO	WO2009111664	9/2009
WO	WO 2006021932	3/2006	WO	WO2009146082	12/2009
WO	WO 2006027586	3/2006	WO	WO2010000085	1/2010
WO	WO2006028347	3/2006	WO	WO2010009100	1/2010
WO	WO2006035351	4/2006	WO	WO2010011833	1/2010
WO	WO2006037802	4/2006	WO	WO2010019778	2/2010
WO	WO2006046648	5/2006	WO	WO2010057049	5/2010
WO	WO2006055892	5/2006	WO	WO2010075115	7/2010
WO	WO2006055956	5/2006	WO	WO2010080765	7/2010
WO	WO2006059338	6/2006	WO	WO2010080843	7/2010
WO	WO2006075016	7/2006	WO	WO2010107563	9/2010
WO	WO2006100620	9/2006	WO	WO2010115194	10/2010
WO	WO2006109072	10/2006	WO	WO2010132331	11/2010
WO	WO2006/123346	11/2006	WO	WO2010135516	11/2010
WO	WO2006116718	11/2006	WO	WO2011068963	6/2011
WO	WO2006119345	11/2006	WO	WO2011133799	10/2011
WO	WO2006127355	11/2006	WO	WO2011159336	12/2011
WO	WO2007001724	1/2007	WO	WO2011159337	12/2011
WO	WO2007001742	1/2007	WO	WO2011159338	12/2011
WO	WO2007013952	2/2007	WO	WO2011159339	12/2011
WO	WO2007014084	2/2007	WO	WO2012104657	8/2012
WO	WO2007014527	2/2007	WO	WO2012158190	11/2012
WO	WO2007021496	2/2007	WO	WO2013012869	1/2013
WO	WO2007027660	3/2007	WO	WO2015112603	7/2015
WO	WO2007028035	3/2007	OTHER PUBLICATIONS		
WO	WO2007036687	4/2007	Consolvo, Sunny et al., "Design Requirement for Technologies that Encourage Physical Activity," CHI 2006 Proceedings, Designing for Tangible Interactions, Apr. 22, 2006, Montreal, Quebec, Canada, pp. 457-466.		
WO	WO2007036741	4/2007	Ferguson et al., "Wireless communication with implanted medical devices using the conductive properties of the body," Expert Rev Med Devices, Jul. 2011, 8(4): 427-433.		
WO	WO2007036746	4/2007	Kendle, Earl R. and Morris, Larry A., "Preliminary Studies in the Development of a Gastric Battery for Fish" (1964). Nebraska Game and Parks Commission White Papers, Conference Presentations, & Manuscripts. Paper 22. p. 1-6.		
WO	WO2007040878	4/2007	Kim et al., "A Semi-Interpenetrating Network System for a Polymer Membrane"; Eur. Polym. J. vol. 33 No. 7; pp. 1009-1014 (1997).		
WO	WO2007067054	6/2007			
WO	WO2007071180	6/2007			
WO	WO2007096810	8/2007			
WO	WO2007101141	9/2007			
WO	WO2007115087	10/2007			
WO	WO2007120946	10/2007			
WO	WO2007127316	11/2007			

(56)

References Cited

OTHER PUBLICATIONS

- McDermott-Wells, P., "What is Bluetooth?", IEEE Potentials, IEEE, New York, NY, vol. 23, No. 5, Dec. 1, 2004, pp. 33-35.
- Sharma, et al., "The Future is Wireless: Advances in Wireless Diagnostic and Therapeutic Technologies in Gastroenterology," Gastroenterology, Elsevier, Philadelphia, PA, vol. 137, No. 2, Aug. 1, 2009, pp. 434-439.
- AADE, "AADE 37th Annual Meeting San Antonio Aug. 4-7, 2010" American Association of Diabetes Educators Aug. 2010; <http://www.diabeteseducator.org/annualmeeting/2010/index.html>; 2 pp.
- Arshak et al., A Review and Adaptation of Methods of Object Tracking to Telemetry Capsules IC-Med; Jan. 2007 vol. 1, No. 1, Issue 1, 12pp.
- "ASGE Technology Status Evaluation Report: wireless capsule endoscopy" American Soc. For Gastrointestinal Endoscopy; Apr. 2006 vol. 63, No. 4; 7 pp.
- Baskiyar, S., "A Real-time Fault Tolerant Intra-body Network" Dept. of Comp. Sci & Soft Eng; Auburn University; Proceedings of the 27th Annual IEEE Conference; 0742-1303/02 (2002) IEEE; 6 pp.
- Bohidar et al., "Dielectric Behavior of Gelatin Solutions and Gels" Colloid Polym Sci (1998) 276:81-86.
- Carlson et al., "Evaluation of a non-invasive respiratory monitoring system for sleeping subjects" Physiological Measurement (1999) 20(1): 53.
- Coury, L., "Conductance Measurement Part 1: Theory"; Current Separations, 18:3 (1999) p. 91-96.
- Delvaux et al., "Capsule endoscopy: Technique and indications" Clinical Gastroenterology; Oct. 2008 vol. 22, Issue 5, 1 pp. (Abstract Only).
- Dhar et al., "Electroless nickel plated contacts on porous silicon" Appl. Phys. Lett. 68 (10) pp. 1392-1393 (1996).
- Eldek A., "Design of double dipole antenna with enhanced usable bandwidth for wideband phased array applications" Progress in Electromagnetics Research PIER 59, 1-15 (2006).
- Evanczuk, S., "PIC MCU software library uses human body for secure communications link" EDN Network; edn.com; Feb. 26, 2013 Retrieved from internet Jun. 19, 2013 at <http://www.edn.com/electronics-products/other/4407842/PIC-MCU-software-library-uses-human-body-for-secure-communications-link>; 5 pp.
- Ferguson et al., "Dielectric Constant Studies III Aqueous Gelatin Solutions" J. Chem. Phys. 2, 94 (1934) p. 94-98.
- Furse C. M., "Dipole Antennas" J. Webster (ed). Wiley Encyclopedia of Electrical and Electronics Engineering (1999) p. 575-581.
- Gagliani S., "Put Your Phone, or Skin, on Vibrate" MedGadget; Mar. 2012 <http://medgadget.com/2012/03/put-your-phone-or-skin-on-vibrate.html> 8pp.
- Gilson, D.R. "Molecular dynamics simulation of dipole interactions", Department of Physics, Hull University, Dec. 2002, p. 1-43.
- Given Imaging, "Agile Patency Brochure" (2006) http://www.inclino.no/documents/AgilePatencyBrochure_Global_GMB-0118-01.pdf; 4pp.
- Gonzalez-Guillaumin et al., "Ingestible capsule for impedance and pH monitoring in the esophagus" IEEE Trans Biomed Eng; Dec. 2007 54(12) 1pp. (Abstract Only).
- Greene, "Edible RFID microchip monitor can tell if you take your medicine" Bloomberg Businessweek; Mar. 2010 2 pp.; <http://www.businessweek.com/idg/2010-03-31/edible-rfid-microchip-monitor-can-tell-if-you-take-your-medicine.html>.
- Heydari et al., "Analysis of the PLL jitter due to power/ground and substrate noise"; IEEE Transactions on Circuits and Systems (2004) 51(12): 2404-16.
- Hoover et al., "Rx for health: Engineers design pill that signals it has been swallowed" University of Florida News; Mar. 2010 2pp.; <http://news.ufl.edu/2010/03/31/antenna-pill-2/>.
- Hotz "The Really Smart Phone" The Wall Street Journal, What They Know (2011); 6 pp.; http://online.wsj.com/article/SB10001424052748704547604576263261679848814.html?mod=djemTECH_t.
- ISFET—Ion Sensitive Field-Effect Transistor; MICROSENS S.A. pdf document. First cited by Examiner in Office Action dated Jun. 13, 2011 for U.S. Appl. No. 12/238,345; 4pp.
- Intromedic, MicroCam Innovative Capsule Endoscope Pamphlet. (2006) 8 pp (<http://www.intromedic.com/en/product/productinfo.asp>).
- Jimbo et al., "Gastric-fluid-utilized micro battery for micro medical devices" The Sixth International Workshop on Micro and Nanotechnology for Power Generation and Energy Conservation Applications, (2006) pp. 97-100.
- Jung, S., "Dissolvable 'Transient Electronics' Will Be Good for Your Body and the Environment" MedGadget; Oct. 1, 2012; °Online website: <http://medgadget.com/2012/10/dissolvable-transient-electronics-will-be-good-for-your-body-and-the-environment.html>; downloaded Oct. 24, 2012; 4 pp.
- Juvenile Diabetes Research Foundation International (JDRF), "Artificial Pancreas Project" Jun. (2010); <http://www.artificialpancreasproject.com/>; 3 pp.
- Kamada K., "Electrophoretic deposition assisted by soluble anode" Materials Letters 57 (2003) 2348-2351.
- Li, P-Y, et al. "An electrochemical intraocular drug delivery device", Sensors and Actuators A 143; p. 41-48.; Jul. 2007.
- Lifescan, "OneTouch UltraLink™" <http://www.lifescan.com/products/meters/ultralink>; Jul. 2010 2 pp.
- Lin et al., "Do Physiological Data Relate to Traditional Usability Indexes?" Proceedings of OZCHI 2005, Canberra, Australia (2005) 10 pp.
- Mackay et al., "Radio Telemetry from within the Body Inside Information is Revealed by Tiny Transmitters that can be Swallowed or Implanted in Man or Animal" Science (1991) 1196-1202; 134; American Association for the Advancement of Science, Washington D.C.
- Mackay et al., "Endoradiosonde" Nature, (1957) 1239-1240, 179 Nature Publishing Group.
- Mandryk et al., "A physiological approach for continuously modeling user emotion in interactive play environments" Proceedings of Measuring Behavior (2008) (Maastricht The Netherlands Aug. 26-29) 2 pp.
- Mandryk et al., "Objectively Evaluating Entertainment Technology" Simon Fraser University; CHI (2004) ACM 1-58113-703-6/04/0004; 2 pp.
- McKenzie et al., "Validation of a new telemetric core temperature monitor" J. Therm. Biol. (2004) 29(7-8):605-11.
- Medtronic, "CareLink Therapy Management Software for Diabetes" Jul. 2010; <https://carelink.minimed.com/patient/entry.jsp?bhcp=1>; 1 pp.
- Medtronic, "Carelink™ USB" (2008) http://www.medtronicdiabetes.com/pdf/carelink_usb_factsheet.pdf 2pp.
- Medtronic "The New MiniMed Paradigm® Real-Time Revel™ System" Aug. 2010 <http://www.medtronicdiabetes.com/products/index.html>; 2 pp.
- Medtronic, "Mini Med Paradigm® Revel™ Insulin Pump" Jul. 2010 <http://www.medtronicdiabetes.com/products/insulinpumps/index.html>; 2 pp.
- Medtronic, Mini Med Paradigm™ Veo™ System: Factsheet (2010). <http://www.medtronic-diabetes.com.au/downloads/Paradigm%20Veo%20Factsheet.pdf>; 4 pp.
- Mini Mitter Co, Inc. 510(k) Premarket Notification Mini-Logger for Diagnostic Spirometer. Sep. 21, 1999.
- Mojaverian et al., "Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition" Gastroenterology (1985) 89:(2): 392-7.
- NPL_AntennaBasics.pdf, Radio Antennae, <http://www.erikdeman.de/html/sail018h.htm>; (2008) 3pp.
- O'Brien et al., "The Production and Characterization of Chemically Reactive Porous Coatings of Zirconium Via Unbalanced Magnetron Sputtering" Surface and Coatings Technology (1996) 86-87; 200-206.
- Park, "Medtronic to Buy MiniMed for \$3.7 Billion" (2001) HomeCare; http://homecaremag.com/mag/medical_medtronic_buy_minimed/; 2 pp.
- Platt, D., "Modulation and Deviation" AE6EO, Foothills Amateur Radio Society; Oct. 26, 2007; 61 pp.

(56)

References Cited**OTHER PUBLICATIONS**

- Rolison et al., "Electrically conductive oxide aerogels: new materials in electrochemistry" *J. Mater. Chem.* (2001) 1, 963-980.
- Roulstone, et al., "Studies on Polymer Latex Films: I. A study of latex film morphology" *Polymer International* 24 (1991) pp. 87-94.
- Sanduleanu et al., "Octave tunable, highly linear, RC-ring oscillator with differential fine-coarse tuning, quadrature outputs and amplitude control for fiber optic transceivers" (2002) *IEEE MTT-S International Microwave Symposium Digest* 545-8.
- Santini, J.T. et al., "Microchips as controlled drug delivery-devices", *Agnew. Chem. Int. Ed.* (2000), vol. 39, p. 2396-2407.
- "SensiVida minimally invasive clinical systems" Investor Presentation Oct. 2009 28pp; <http://www.sensividamedtech.com/SensiVidaGeneralOctober09.pdf>.
- Shawgo, R.S. et al. "BioMEMS from drug delivery", *Current Opinion in Solid State and Material Science* 6; May 2002, p. 329-334.
- Shin et al., "A Simple Route to Metal Nanodots and Nanoporous Metal Films"; *Nano Letters*, vol. 2, No. 9 (2002) pp. 933-936.
- "Smartlife awarded patent for knitted transducer" *Innovation in Textiles News*: <http://www.innovationintextiles.com/articles/208.php>; 2pp. Aug. 2009.
- Solanas et al., "RFID Technology for the Health Care Sector" *Recent Patents on Electrical Engineering* (2008) 1, 22-31.
- Soper, S.A. et al. "Bio-Mems Technologies and Applications", Chapter 12, "MEME for Drug Delivery", p. 325-346 (2007).
- Swedberg, "University Team Sees Ingestible RFID Tag as a Boon to Clinical Trials" *RFID Journal* Apr. 27, 2010; <http://www.rfidjournal.com/article/view/7560/1> 3pp.
- Tajalli et al., "Improving the power-delay performance in subthreshold source-coupled logic circuits" *Integrated Circuit and System Design. Power and Timing Modeling, Optimization and Simulation*, Springer Berlin Heidelberg (2008) 21-30.
- Tatbul et al., "Confidence-based data management for personal area sensor networks" *ACM International Conference Proceeding Series* (2004) 72.
- Tierney, M.J. et al "Electroreleasing Composite Membranes for Delivery of Insulin and other Biomacromolecules", *J. Electrochem. Soc.*, vol. 137, No. 6, Jun. 1990, p. 2005-2006.
- Trutag, Technologies, Inc., *Spectral Microtags for Authentication and Anti-Counterfeiting*; "Product Authentication and Brand Protection Solutions"; <http://www.trutags.com/>; downloaded Feb. 12, 2013; 1 pp.
- U.S. Appl. No. 12/238,345, filed Sep. 25, 2008, Hooman et al., Non-Final Office Action mailed Jun. 13, 2011 22pp.
- Walkey, "MOSFET Structure and Processing"; 97.398* *Physical Electronics Lecture* 20; First cited by Examiner in Office Action dated Jun. 13, 2011 for U.S. Appl. No. 12/238,345; 24 pp.
- Watson, et al., "Determination of the relationship between the pH and conductivity of gastric juice" *Physiol Meas.* 17 (1996) pp. 21-27.
- Winter, J. et al. "The material properties of gelatin gels"; *USA Ballistic Research Laboratories*, Mar. 1975, p. 1-157.
- Wongmanerod et al., "Determination of pore size distribution and surface area of thin porous silicon layers by spectroscopic ellipsometry" *Applied Surface Science* 172 (2001) 117-125.
- Xiaoming et al., "A telemedicine system for wireless home healthcare based on bluetooth and the Internet" *Telemedicine Journal and e-health* (2004) 10(S2): S110-6.
- Yang et al., "Fast-switching frequency synthesizer with a discriminator-aided phase detector" *IEEE Journal of Solid-State Circuits* (2000) 35(10): 1445-52.
- Zimmerman, "Personal Area Networks: Near-field intrabody communication" *IBM Systems Journal* (1996) 35 (3-4):609-17.
- Zworkin, "A Radio Pill" *Nature*, (1957) 898, 179 *Nature Publishing Group*.




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5




FIG. 7




FIG. 6




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E




FIG. 9F




FIG. 10A




FIG. 10B




FIG. 11

IN-BODY DEVICE WITH VIRTUAL DIPOLE SIGNAL AMPLIFICATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/238,345, entitled IN-BODY DEVICE WITH VIRTUAL DIPOLE SIGNAL AMPLIFICATION, filed Sep. 25, 2008, now U.S. Pat. No. 8,961,412, which application, pursuant to 35 U.S.C. §119 (e), claims priority to the filing date of U.S. Provisional Patent Application Ser. No. 60/975,108 filed on Sep. 25, 2007; the disclosures of which are herein incorporated by reference.

INTRODUCTION

As medical technology advances, many diagnostic and therapeutic activities are carried out with increasingly small implantable medical or ingestible medical devices. Implantable and ingestible medical devices can be configured to perform a variety of different functions, including but not limited to: diagnostic functions, e.g., where the devices include one or more sensors; therapeutic functions, e.g., where the devices enable therapeutic action, such as delivery of an electrical pulse, delivery of a pharmaceutically active agent; etc.

With implantable and ingestible medical and related technologies, there is always a desire to make the devices smaller, e.g., to provide for increased ease of use, etc. To decrease size, individual components of the devices must be designed with a reduced overall physical size while maintaining functionality.

SUMMARY

Virtual dipole signal amplification for in-body devices, such as implantable and ingestible devices, is provided. Aspects of the in-body virtual dipole signal transmission elements include two or more transmitters separated by a signal amplifier. The signal amplifier provides a virtual dipole that is longer than the actual dipole. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A to 1B provide various views of an identifier with a signal amplification element according to an embodiment of the invention.

FIG. 2 provides a side view of an identifier according to another embodiment of the invention.

FIGS. 3A and B provide a side view of an identifier according to another embodiment of the invention.

FIGS. 4A to 4C provide a view of a three-dimensional signal amplification element of the invention.

FIG. 5 provides a view of a composite signal amplification element.

FIGS. 6 and 7 provide views of fabrication protocols that may be employed for fabricating identifiers of the invention.

FIGS. 8A to 8B illustrate embodiments of an IEM where the signal amplification element is fabricated from two prefabricated skirt components. FIG. 8C provides a view of yet another fabrication protocol that may be employed to

produce tablet IEMs, according to certain embodiments of the invention. FIG. 8D provides another embodiment of an IEM.

FIGS. 9A to 9F illustrate various embodiments for fabricating gel cap formulations that include identifiers of the invention.

FIGS. 10A to 10B illustrate a capsule configuration according to another embodiment of the invention, as well as a method for its fabrication.

FIG. 11 provides detail of certain implementations of an electronic circuit of various embodiments of the invention.

DETAILED DESCRIPTION

Virtual dipole signal amplification for in-body devices, such as implantable and ingestible devices, is provided. Aspects of the in-body deployable antennas of the invention include antennas configured to go from a first configuration to a second configuration following placement in a living body, e.g., via ingestion or implantation. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.

In further describing the invention in greater detail, embodiments of the virtual dipole signal transmission elements and in-body devices that include the same are reviewed first, followed by a discussion of systems having devices that include the in-body devices, and methods of using such devices and systems. Also reviewed in greater detail below are kits that include the in-body devices of the invention.

In-Body Devices Having Virtual Dipole Signal Transmission Elements

As summarized above, the invention provides in-body devices having virtual dipole signal transmission elements. An in-body device is a device that is configured to be used inside of a living body. Examples of in-body devices include, but are not limited to: implantable devices, e.g., implantable therapeutic devices, such as but not limited to stents, drug delivery devices, orthopedic implants, etc., implantable diagnostic devices, e.g., sensors, biomarker recorders, etc.; and ingestible devices, e.g., ingestible event markers (e.g., as described in greater detail below), etc.

One type of in-body device in which the virtual dipole signal transmission elements of the invention find use is an ingestible event marker. For ease of description, the in-body devices of the invention will now be further described in terms of embodiments where the virtual dipole signal transmission element is part of an identifier of an ingestible event marker. However, as indicated above, the virtual dipole signal transmission elements of the invention find use in devices other than ingestible event markers, and therefore are not limited to those configured for use in ingestible event markers (IEM). Ingestible event markers are compositions that include an identifier and, in certain embodiments, a vehicle, where the vehicle may or may not include an active agent. Ingestible event markers of interest include those described in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled "Pharma-Informatics System"; PCT application serial no. PCT/US2007/022257 filed on Oct. 17, 2007 and titled "In-vivo Low Voltage Oscillator for Medical Devices"; PCT application serial no. PCT/US2007/82563 filed on Oct. 25, 2007 and titled "Controlled Activation Ingestible Identifier"; U.S. patent application Ser. No. 11/776,480 filed Jul. 11, 2007 entitled "Acoustic Pharma Informatics System"; PCT/

US2008/52845 filed on Feb. 1, 2008 and titled "Ingestible Event Marker Systems"; PCT/US08/53999 filed Feb. 14, 2008 and titled "In-Body Power Source Having High Surface Area Electrode," the disclosures of which applications (and particularly battery configurations disclosed therein) are herein incorporated by reference.

The identifier of the IEM compositions is one that generates (i.e., emits) a detectable signal upon contact of the identifier with a target physiological location (or locations) depending on the particular configuration of the identifier. The identifiers of the present compositions may vary depending on the particular embodiment and intended application of the composition so long as they are activated (i.e., turned on) upon contact with a target physiological location, e.g., stomach. As such, an ingestible event marker may include an identifier that emits a signal when activated at a target site, e.g., when it contacts a target body (i.e., physiological) site. The identifier may be any component or device that is capable of providing a detectable signal following activation, e.g., upon contact with the target site. Identifiers according to embodiments of the invention include a signal generation component. In certain embodiments, the identifier emits a signal once the composition comes into contact with a physiological target site, e.g., the stomach. Depending on the embodiment, the target physiological site or location may vary, where representative target physiological sites of interest include, but are not limited to: a location in the gastrointestinal tract, such as the mouth, esophagus, stomach, small intestine, large intestine, etc. In certain embodiments, the identifier is configured to be activated upon contact with fluid at the target site, e.g., stomach fluid, regardless of the particular composition of the target site. In some embodiments, the identifier is configured to be activated by interrogation, following contact of the composition with a target physiological site. In some embodiments, the identifier is configured to be activated at a target site, wherein the target site is reached after a specified period of time.

Depending on the needs of a particular application, the signal obtained from the identifier may be a generic signal, e.g., a signal that merely identifies that the composition has contacted the target site, or a unique signal, e.g., a signal which in some way uniquely identifies that a particular ingestible event marker from a group or plurality of different markers in a batch has contacted a target physiological site. As such, the identifier may be one that, when employed with a batch of unit dosages, e.g., a batch of tablets, emits a signal which cannot be distinguished from the signal emitted by the identifier of any other unit dosage member of the batch. In yet other embodiments, each member of the batch has an identifier that emits a unique signal, at least with respect to all the other identifiers of the members of the batch. As such, each identifier of the batch emits a signal that uniquely identifies that particular identifier in the batch, at least relative to all the other identifiers of the batch. Accordingly, in certain embodiments the identifier emits a unique signal that distinguishes one class of identifier from other types of identifiers. In certain embodiments, the identifier emits a unique signal that distinguishes that identifier from other identifiers. In certain embodiments, the identifier emits a signal that is unique, i.e., distinguishable, from a signal emitted by any other identifier ever produced, where such a signal may be viewed as a universally unique signal (e.g., analogous to a human fingerprint which is distinct from any other fingerprint of any other individual and therefore uniquely identifies an individual on a universal level). In one embodiment, the signal may either directly convey infor-

mation about a given event, or provide an identifying code, which may be used to retrieve information about the event from a database, i.e., a database linking identifying codes with compositions.

The identifier may generate a variety of different types of signals, including but not limited to: RF signals, magnetic signals, conductive (near field) signals, acoustic signals, etc. Of interest in certain embodiments are the specific signals described in pending PCT application serial no. PCT/US2006/16370 filed on Apr. 28, 2006; the disclosures of various types of signals in this application being specifically incorporated herein by reference. The transmission time of the identifier may vary, where in certain embodiments the transmission time may range from about 0.1 μ sec to about 48 hours or longer, e.g., from about 0.1 μ sec to about 24 hours or longer, such as from about 0.1 μ sec to about 4 hours or longer, such as from about 1 sec to about 4 hours, including from about 1 minute to about 10 minutes. Depending on the given embodiment, the identifier may transmit a given signal once. Alternatively, the identifier may be configured transmit a signal with the same information, i.e., identical signals, two or more times, where the collection of discrete identical signals may be collectively referred to as a redundant signal.

The identifiers may vary depending on the particular embodiment and intended application of the composition so long as they are activated (i.e., turned on) upon contact with a target physiological location, e.g., stomach. As such, the identifier may be an identifier that emits a signal when it contacts a target body (i.e., physiological) site. In addition or alternatively, the identifier may be an identifier that emits a signal when interrogated after it has been activated. Identifier components of embodiments of the invention have: (a) an activation component; and (b) a signal generation component, where the signal generation component is activated by the activation component to produce an identifying signal, e.g., as described above.

The activation component is a component that activates the signal generation element of the identifier to provide a signal, e.g., by emission or upon interrogation, following contact of the composition with a target physiological site of interest, such as the stomach. As reviewed in co-pending PCT application serial no. PCT/US2006/016370, activation of the identifier may be achieved in a number of different ways, where such approaches include, but are not limited to: battery completion, battery connection, etc. The different activation approaches disclosed in this co-pending application may be readily adapted to provide activation, as described herein, and as such are herein incorporated by reference in their entirety.

Embodiments of activation elements based on battery completion formats employ in-body battery sources of the invention. When activated, the in-body battery power source includes a cathode, an anode, and an electrolyte. In one such embodiment, when the cathode and anode come into contact with stomach fluid, the stomach fluid acts as the electrolyte component of the battery, such that the added component of the stomach fluid thus completes the battery.

In certain embodiments, the battery that is employed is one that comprises two dissimilar electrochemical materials which constitute the two electrodes (e.g., anode and cathode) of the battery. When the electrode materials come in contact with the body fluid, such as stomach acid or other types of fluid (either alone or in combination with a dried conductive medium precursor), a potential difference, i.e., a voltage, is generated between the electrodes as a result of the respective oxidation and reduction reactions occurring at the two electrodes (such that a voltaic cell or battery is pro-

duced). Accordingly, in embodiments of the invention, power sources are configured such that when the two dissimilar materials are exposed to the target site, e.g., the stomach, the digestive tract, etc., a voltage is generated. The two dissimilar materials in an electrolyte are at different potentials. In certain of these embodiments, the in-body battery power source may be viewed as a power source that exploits electrochemical reaction in an ionic solution such as gastric fluid, blood, or other bodily fluids and some tissues.

The dissimilar materials making up the electrodes can be made of any two materials appropriate to the environment in which the identifier will be operating. The active materials are any pair of materials with different electrochemical potentials. For instance, in some embodiments where the ionic solution comprises stomach acids, electrodes may be made of a noble metal (e.g., gold, silver, platinum, palladium or the like) so that they do not corrode prematurely. Alternatively, the electrodes can be fabricated of aluminum or any other conductive material whose survival time in the applicable ionic solution is long enough to allow the identifier to perform its intended function. Suitable materials are not restricted to metals, and in certain embodiments the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuI). With respect to the active electrode materials, any pairing of substances—metals, salts, or intercalation compounds—that have suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.

A variety of different materials may be employed as the battery electrodes. In certain embodiments, electrode materials are chosen to provide for a voltage upon contact with the target physiological site, (e.g., the stomach), sufficient to drive the signal generation element of the identifier. In certain embodiments, the voltage provided by the electrode materials upon contact of the metals of the power source with the target physiological site is 0.001 V or higher, including 0.01 V or higher, such as 0.1 V or higher, e.g., 0.3 V or higher, including 0.5 volts or higher, and including 1.0 volts or higher, where in certain embodiments, the voltage ranges from about 0.001 to about 10 volts, such as from about 0.01 to about 10 V.

Materials and pairings of interest include, but are not limited to those reported in Table 1 below.

TABLE 1

	Anode	Cathode
Metals	Magnesium, Zinc Sodium (†), Lithium (†) Iron and alloys thereof, e.g., Al and Zn alloys of Mg	
Salts		Copper salts: iodide, chloride, bromide, sulfate, formate, (other anions possible) Fe ³⁺ salts: e.g. orthophosphate, pyrophosphate, (other anions possible) Oxygen or hydrogen (††) on platinum, gold or other catalytic surfaces
Intercalation compounds	Graphite with Li, K, Ca, Na, Mg	Vanadium oxide Manganese oxide

† Protected anodes: certain high energy anode material such as Li, Na, and other alkali metals are unstable in their pure form in the presence of water or oxygen. These may however be used in an aqueous environment if stabilized. One example of this stabilization is the so-called “protected lithium anode” developed by Polyplus Corporation (Berkeley, CA), where a polymer film is deposited on the surface of lithium metal to protect it from rapid oxidation and allow its use in aqueous environment or air ambient. (Polyplus has IP pending on this).

†† Dissolved oxygen can also serve as a cathode. In this case, the dissolved oxygen in the bodily fluids would be reduced to OH⁻ at a suitable catalytic surface such as Pt or gold. Also of interest dissolved hydrogen in a hydrogen reduction reaction.

In certain embodiments, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage output of the battery. Non-metals that may be used as doping agents in certain embodiments include, but are not limited to: sulfur, iodine and the like.

In certain embodiments, the electrode materials are cuprous iodine (CuI) or cuprous chloride (CuCl) as the cathode and magnesium (Mg) metal or magnesium alloy as the anode. Embodiments of the present invention use electrode materials that are not harmful to the human body.

Depending on the particular embodiment, the cathode and anode may be present on the same support or different supports, e.g., where two or more different supports are bonded together to produce the battery structure, e.g., as is present in a “flip-chip” embodiment. Similarly, the number of cathodes and anodes in a given battery may vary greatly depending on the embodiment, e.g., where a given embodiment may include a single battery having one anode and cathode, a single battery having multiple anodes and/or cathodes, or two or more distinct batteries each made up of one or more cathodes and/or anodes. Battery configurations of interest include, but are not limited to, those disclosed in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled “Pharma-Informatics System”; PCT application serial no. PCT/US2007/022257 filed on Oct. 17, 2007 and titled “In-vivo Low Voltage Oscillator for Medical Devices”; PCT application serial no. PCT/US2007/82563 filed on Oct. 25, 2007 and titled “Controlled Activation Ingestible Identifier”; U.S. patent application Ser. No. 11/776,480 filed Jul. 11, 2007 entitled “Acoustic Pharma Informatics System”; PCT/US2008/52845 filed on Feb. 1, 2008 and titled “Ingestible Event Marker Systems”; PCT/US08/53999 filed Feb. 14, 2008 and titled “In-Body Power Source Having High Surface Area Electrode,” the disclosures of which applications (and particularly battery configurations disclosed therein) are herein incorporated by reference.

In addition to the activation component, e.g., battery component, as described above, ingestible event markers of the invention include a solid support. The solid support may vary depending on the nature of the IEM. In certain embodiments, the solid support is small, e.g., where it is dimensioned to have a width ranging from about 0.01 mm to about 100 mm, e.g., from about 0.1 mm to about 20 mm, including from about 0.5 mm to about 2 mm; a length ranging from about 0.01 mm to about 100 mm, e.g., from about 0.1 mm to about 20 mm, including from about 0.5 mm to about 2 mm, and a height ranging from about 0.01 mm to about 10 mm, e.g., from about 0.05 mm to about 2 mm, including from about 0.1 mm to about 0.5 mm. The solid support element may take a variety of different configurations, such as but not limited to: a chip configuration, a cylinder configuration, a spherical configuration, a disc configuration, etc, where a particular configuration may be selected based on intended application, method of manufacture, etc. While the material from which the solid support is fabricated may vary considerably depending on the particular device for which the antenna is configured for use. In certain embodiments the solid support is made up of a semiconductor material, e.g., silicon.

In certain embodiments, the solid support is a semiconductor support that includes one or more circuit elements, where in certain embodiments the support is an integrated circuit. When present, integrated circuits include a number of distinct functional blocks, i.e., modules. Within a given solid support, at least some of, e.g., two or more, up to and including all of, the functional blocks, e.g., power source,

processor, transmitter, etc., may be present in a single integrated circuit. The phrase "single integrated circuit" refers to a single circuit structure that includes all of the different desired functional blocks for the device. In these embodiments, the integrated circuit is a monolithic integrated circuit (also known as IC, microcircuit, microchip, silicon chip, computer chip or chip) that is a miniaturized electronic circuit (which may include semiconductor devices, as well as passive components) that has been manufactured in the surface of a thin substrate of semiconductor material. The integrated circuits of certain embodiments of the present invention may be hybrid integrated circuits, which are miniaturized electronic circuits constructed of individual semiconductor devices, as well as passive components, bonded to a substrate or circuit board.

In addition to the activation component of the identifier described above, identifiers of the invention also include a signal generation component. The signal generation component of the identifier element is a structure that, upon activation by the activation component, emits a detectable signal, e.g., that can be received by a receiver, e.g., as described in greater detail below. The signal generation component of certain embodiments can be any convenient device that is capable of producing a detectable signal and/or modulating transduced broadcast power, upon activation by the activation component. Detectable signals of interest include, but are not limited to: conductive signals, acoustic signals, etc. As reviewed above, the signals emitted by the signal generator may be generic or unique signals, where representative types of signals of interest include, but are not limited to: frequency shift coded signals; amplitude modulation signals; frequency modulation signals; etc.

In certain embodiments, the signal generation element includes circuitry, as developed in more detail below, which produces or generates the signal. The type of circuitry chosen may depend, at least in part, on the driving power that is supplied by the power source of the identifier. For example, where the driving power is 1.2 volts or above, standard CMOS circuitry may be employed. In other embodiments where the driving power ranges from about 0.7 to about 1.2 V, sub-threshold circuit designs may be employed. For driving powers of about 0.7 V or less, zero-threshold transistor designs may be employed.

In certain embodiments, the signal generation component includes a voltage-controlled oscillator (VCO) that can generate a digital clock signal in response to activation by the activation component. The VCO can be controlled by a digital circuit, which is assigned an address and which can control the VCO with a control voltage. This digital control circuit can be embedded onto a chip that includes the activation component and oscillator. Using amplitude modulation or phase shift keying to encode the address, an identifying signal is transmitted.

As summarized above, a component of the devices of the invention is an identifier that emits a signal when it contacts a target site. The identifier of embodiments of the invention includes a pair of transmission elements having an actual dipole length and a signal amplification element that produces a virtual dipole length between the pair of transmission elements that is larger than the actual dipole length. While the length of the virtual dipole may vary so long as its length is greater than the length of the actual dipole, in certain instances the length of the virtual dipole is 2 or more times, such as three or more times, e.g., 5 or more times, 20 or more times, etc., longer than the length of the actual dipole that exists between the pair of transmission elements. As the length of an actual dipole in a given identifier may

vary, ranging in certain instances from 100 μm to 2 cm, such as 300 μm to 1 mm, the length of the virtual dipole may range, in certain instances, from 200 μm to 20 cm, such as 600 μm to 20 mm.

The signal amplification element may have a variety of different configurations, so long as it serves to provide a virtual dipole having a length that is longer than that of the actual dipole length between two or more, such as a pair, of signal transmission elements. In certain embodiments, the signal amplification element is a structure that is positioned between the pair of signal transmission elements. The signal amplification element may have a two-dimensional or three-dimensional configuration, and have any convenient shape, such as square, disc, triangular, ovoid, irregular, etc., as developed in greater detail below. The length of the virtual dipole provided by the signal amplification element is, in certain instances, dependent on the particular shape of the signal amplification element. For example, where the signal amplification element has a disc configuration, as developed in greater detail below, the length of the virtual dipole is substantially the same as, if not identical to, the radius of the disc.

The pair of transmission elements are, in certain instances, a pair of electrodes positioned on opposing sides of a solid support, e.g., where the solid support comprises an integrated circuit. For example, where the integrated circuit has an upper electrode and lower electrode on opposing sides or surfaces of the IC, the signal amplification element may be an insulative material (or composite material) positioned between the upper and lower electrodes. The outer edge of the signal amplification may or may not extend beyond the edge of the electrodes, where examples of these differing embodiments are reviewed in greater detail below.

FIG. 1A to provide views of an embodiment of an identifier according to the invention which has a signal amplification element that extends beyond the outer edges of the signal transmission elements to provide a virtual dipole having a length that is longer than the actual dipole between the signal transmission elements. As shown in FIG. 1A, identifier 10 includes integrated circuit 12, having an upper electrode 14 (which may comprise two distinct material layers) and a lower electrode 16. Also shown is disc shaped signal amplification element 18.

FIG. 1B provides an overhead view of the identifier shown in FIG. 1A, showing the disc shape of upper electrode 14 and the positioning of the upper electrode in the center of disc shaped signal amplification element 18. The distance that the edge of the signal amplification element may extend beyond the edge of electrodes may vary, and in certain embodiments is 0.05 mm or more, e.g., 0.1 mm or more, including 1.0 mm or more, such as 5.0 mm or more and including 10 mm or more, where the distance may not exceed 100 mm in certain embodiments.

As can be seen in the embodiment depicted in FIGS. 1A to 1B, the upper and lower electrodes are planar electrodes, where these electrodes may have any convenient shape, e.g., square, disc, etc. The disc shaped signal amplification element 18 is a planar disc structure, where the edge of the signal amplification element extends beyond the edge of the planar upper and lower electrodes. In the depicted embodiment, the radius of the signal amplification element is longer than the radius of the upper and lower electrodes, e.g., by 1 mm or more, such as by 10 mm or more.

It is noted that in any given embodiment, the signal amplification element may or may not extend beyond the edge of the electrodes. For example, in one embodiment as shown in FIGS. 1A to 1B, the signal amplification element

extends beyond the edge of the upper and lower electrodes. However, in other embodiments, the signal amplification element may have an edge commensurate with the edge of one of the electrodes, e.g., the bottom electrode, such that it does not extend beyond the edge of both electrodes. See e.g., FIG. 3, where signal amplification element 38 has an edge that extends beyond the edge of top electrode 34 but not beyond the edge of bottom electrode 36.

FIG. 2 provides a view of an alternative embodiment of an identifier according to the invention. In FIG. 2, identifier 20 includes upper and lower electrodes 24 and 26, and signal amplification element 28. Signal amplification element 28 is configured so that its upper and lower surfaces (25 and 27, respectively) extend a short distance (denoted "x" in the figure) above and below the upper and lower surfaces of the electrodes, such that the electrode elements are recessed relative to the signal amplification element. This configuration not only provides for a desired longer virtual dipole, but also provides for uniform consumption of the electrode materials upon contact of the identifier with the target site, as reviewed in greater detail below. When present, the distance "x" that the electrodes are recessed relative to the surface of the signal amplification element may vary, and in certain embodiments ranges from 0.01 to 10 mm, such as 0.01 to 1 mm and including 10 to 300 μm . The two distances "x" may be the same or different, as desired.

FIGS. 3A and 3B provide top and side views of another embodiment of an identifier according to the invention, where the identifier includes two distinct dipoles and is illustrative of identifier embodiments that have multiple dipoles, such as two or more, 3 or more, 5 or more, etc., dipoles. In FIGS. 3A and 3B, identifier 30 includes a bottom electrode 36 and a first top electrode 34. Also shown is second top electrode 35. Embodiments of identifiers having two or more distinct dipoles may be configured to transmit from each dipole at the same time or at different times. Also shown are integrated circuit 32 and signal amplification element 38. As shown in FIG. 3A, signal amplification element 38 has an edge that is coextensive with the edge of bottom electrode 36, but extends beyond the edge of first top electrode 34 and second top electrode 35.

As indicated above, the signal amplification elements may have "two-dimensional" or "three-dimensional" configurations. Examples of "two-dimensional" configurations are shown in FIGS. 1 to 3, where the insulative material has a disc configuration in which upper and lower surfaces are planar and are present in parallel planes.

Examples of "three-dimensional" configurations are shown in FIGS. 4A to 4C. For three-dimensional embodiments, at least one of the upper and lower surfaces of the signal amplification element is not planar and the upper and lower surfaces are not present in parallel planes. The angle between any two planes in a three-dimensional configuration may vary, ranging in certain embodiments from 0 to 180°, such as from 45 to 135°. For example, in the embodiment shown in FIG. 4A, identifier 40 includes a three-dimensional shaped signal amplification element 48 upon which three different transmission elements 41, 42 and 43 are present. The integrated circuits and electrode may be positioned at any convenient location in this three-dimension structure, e.g., at the center, on one side, etc. where the structure may include more than one integrated circuit component. FIG. 4B provides view of another embodiment of an identifier with a three-dimensional signal amplification element, 44 and transmission elements 45 and 46. FIG. 4C provides a view of another embodiment of an identifier with a three-dimensional signal amplification element 47 and IC 49 that

passes through the identifier and has transmission elements, e.g., electrodes, on opposing surfaces.

A given identifier may include one or more integrated circuit/transmission element structures combined with one or more signal amplification elements. For example, identifiers may include two or more circuit/transmission element structures each with their own signal amplification element. An example of such an embodiment would be where an identifier includes two or more distinct three-dimensional signal amplification elements positioned to provide multi-directional signal broadcast, and each signal amplification element has its own integrated circuit/transmission element structure. Alternatively, identifiers may include two or more circuit/transmission element structures, each present in the same signal amplification element. In those embodiments where two or more circuit/transmission element structures are present in the same signal amplification element, they may be oriented relative to each other in any desired format, e.g., to eliminate "blind spots" in transmission, such that signal spans the entire transmission field of interest. Yet other embodiments that may include multiple integrated circuit/transmission element structures are embodiments where the identifier is configured to be activated at, and therefore provide distinct signals from, two or more different physiological locations, e.g., distinct locations of the gastrointestinal tract, such as stomach and small intestine. For example, a given identifier may include a first integrated circuit/transmission element that emits a first signal upon contact with the stomach and second integrated circuit/transmission element that emits a second signal upon contact with the small intestine.

The signal amplification element may be fabricated from a number of different materials, where the signal amplification element may be made of a single material or be a composite of two or more different types of materials. In choosing a suitable material or materials, one characteristic of interest is mechanical strength. As indicated above, the signal amplification material may be a composite structure of two or more materials, e.g., an insulative material deposited on a metallic layer, e.g. as shown in FIG. 5. In FIG. 5, lower portion 52 is an insulative material, e.g., as describe above. Upper portion 54 is a metallic layer, e.g., Pt, Cu, Au, Ti, W, or other metal. Such a structure is useful in a variety of different types of identifiers, such as RFID identifiers. In such embodiments, the metallic layer may be deposited on the insulating layer, or vice versa. In yet other embodiments, the metallic layer may be encased in the insulating layer.

In certain instances, the signal amplification element will have a mechanical strength sufficient to withstand the mechanical forces typical of the gastrointestinal (GI) tract without folding onto itself and losing its shape. This desired mechanical strength may be chosen to last for at least the duration of the transmitted signal, which may be 1 second or longer, such as at least 1 minute or longer, up to 6 hours or longer. In certain embodiments, the desired mechanical strength is selected to last for a period of time ranging from 1 to 30 minutes. The desired mechanical strength can be achieved by proper selection of polymer or fillers, or mechanical design (e.g., lamination of multiple layers, or curvature of the skirt surface) to increase the mechanical strength of the final structure.

Signal amplification elements of the invention are ones that are electrically insulating. As such, the materials from which the signal amplification elements are fabricated are electrically insulating materials. A given material is electrically insulating if it has a resistivity that is 2 times or greater

than the medium in which the device operates (e.g., stomach fluid), such as 10 times or greater, including 100 times or greater than the medium in which the device operates.

Another characteristic of interest for the signal amplification element is ingestibility and low risk of blockage. It is desirable that the signal amplification element be made of safe and ingestible material, such as food additives or pharmaceutical excipients. It may be further desirable to make the signal amplification element in such a way to ensure low risk for blockage of the GI tract by one or more devices. This can be achieved via chemical or physical dissolution or digestion of the amplification element material, or mechanical breakdown of the signal amplification element, or a combination of the two. For example, the signal amplification element can contain one or more materials that chemically or physically dissolve in GI fluids after a certain amount of time. The material can also be selected to become soluble upon reaching certain parts of the GI tract where the chemical environment is different, for example, a change in pH (e.g., from pH 1-2 in stomach to pH>5 in intestine) or enzymatic components (such as enzymes present in the colon). The signal amplification element may also be mechanically designed to have a weak point that dissolves and allows the entire structure to break up. The signal amplification element may be constituted of several layers, for example an inner soluble or swelling layer and an outer layer that controls the dissolution rate of the inner layer; after a certain amount of time, the inner layer dissolves or swells, bursting apart the entire structure. The signal amplification element does not need to be fully soluble or digestible to eliminate the risk of blockage; it is sufficient that the signal amplification element becomes mechanically pliable or friable enough that it folds or breaks up under modest mechanical strain in the GI tract.

In certain embodiments, the signal amplification element may also serve as a reservoir of active pharmaceutical agents. The transmitter will then serve the dual purpose of indicating pill ingestion and serving as a drug release agent. For example, the signal amplification element may be an integral part of a capsule. Or it may be a laminate of several layers, one or more of which is a controlled release film that swells and releases an active ingredient.

The surface of the signal amplification element may also contain an anti-adhesion layer that prevents a transmitter from adhering to the stomach lining or getting blocked by objects in the GI tract such as food residue. An anti-adhesion film may also be used to prevent two or more transmitting devices from adhering to each other and blocking each other's signal.

In various aspects, the signal amplification element may be fabricated from various materials, categories of materials, and/or combinations of materials. The categories include, for example, but are not limited to: film forming or binding/adhesive agents; fillers; soluble materials or disintegrants; plasticizing agents; coatings; and wetting agents.

The film forming or binding/adhesive agents include, for example, but are not limited to: agar; carageenan; cellulose acetate; chitosan; copovidone; ethyl cellulose; gelatin; gums (e.g., acacia, xanthan, guar, etc.); sugars (e.g., lactose, mannitol, xylitol, etc.); hydrogels (e.g., hydroxyethyl cellulose, sodium alginate, urethane, etc.); acrylic acid polymers, cellulose acetate, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, ethylcellulose, methacrylic acid copolymer, methyl hydroxyethylcellulose, polyethylene glycol, polyvinyl acetate phthalate, polyvinyl alcohol, povidone, starch, carbomers, dextrin, hypromellose, poly(methylvinyl ether/ma-

leic anhydride), chitosan, glyceryl monooleate, polyethylene oxide, polycarbophil, acacia, ceretonia, confectioner's sugar, cottonseed oil, dextrates, dextrose, glyceryl behenate, hydrogenated vegetable oil, hydroxypropyl starch, inulin, lactose, glucose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, poloxamer, polycarbophil, polydextrose, polymethacrylates, stearic acid, sucrose, sunflower oil, zein, aluminum stearate, calcium silicate, colloidal silicon dioxide, glyceryl palmitostearate, pectin, polyethylene alkyl ethers, propylene carbonate, sodium ascorbate, zinc acetate, urethane, ammonium alginate, chlorpheniramine maleate, dibutyl phthalate, dibutyl sebacate, diethyl phthalate, dimethyl phthalate, ethyl lactate, vanillin, shellac, and the like.

The fillers include, for example, but are not limited to: oxides, e.g., titanium dioxide, magnesium oxide, etc.; silicates, e.g., magnesium silicate; phosphates, e.g., dicalcium phosphate; carbonates and bicarbonates; starches; cellulosic materials, e.g., microcrystalline cellulose; acacia, agar, alginate, inulin, carbomers, carboxymethylcellulose, carrageenan, cellulose acetate phthalate, ceretonia, chitosan, confectioner's sugar, copovidone, cottonseed oil, dextrates, dextrin, dextrose, ethylcellulose, gelatin, glyceryl behenate, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, inulin, lactose, glucose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, microcrystalline cellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, povidone, sodium alginate, starch, stearic acid, sucrose, sunflower oil, zein, bentonite, calcium stearate, carbomers, cellulose, colloidal silicon dioxide, kaolin, maltitol, sesame oil, sodium starch glycolate, sorbitan esters, tragacanth, xanthan gum, mannitol, ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, erythritol, fructose, fumaric acid, glyceryl palmitostearate, isomalt, kaolin, lactitol, magnesium carbonate, magnesium oxide, mannitol, simethicone, trehalose, xylitol, and the like.

The soluble materials or disintegrants include, for example, but are not limited to: alginates (e.g., sodium or calcium); crosscarmellose sodium, carboxymethyl cellulose sodium, crospovidone, hydroxypropyl, cellulose, hydroxypropyl methyl cellulose, hypromellose, lactose manitol, polyvinyl alcohol, and salts such as sodium or potassium chloride, alginic acid, calcium alginate, carboxymethylcellulose, cellulose, chitosan, colloidal silicon dioxide, crosscarmellose sodium, crospovidone, docusate sodium, guar gum, hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, polacrilin potassium, povidone, sodium alginate, sodium starch glycolate, starch, and the like.

The plasticizing agents include, for example, but are not limited to dibutyl sebacate, triethyl citrate, and triacetin, acetyltributyl citrate, acetyltriethyl citrate, benzyl benzoate, cellulose acetate phthalate, chlorbutanol, dextrin, dibutyl phthalate, dibutyl sebacate, diethyl phthalate, dimethyl phthalate, glycerin, glycerin monostearate, hypromellose phthalate, mannitol, mineral oil, lanolin alcohols, palmitic acid, polyethylene glycol, polymethacrylate, polyvinyl acetate phthalate, propylene glycol, 2-pyrrolidone, sorbitol, stearic acid, triacetin, tributyl citrate, triethanolamine, triethyl citrate, and the like.

Coatings include, for example, but are not limited to polymethacrylates (pH sensitive) and polyvinyl acetate phthalate (pH sensitive), and hydroxypropyl methylcellulose (moisture barrier), acetyltributyl citrate, acetyltriethyl cit-

13

rate, calcium carbonate, carboxymethylcellulose sodium, carnauba wax, cellulose acetate, cellulose acetate phthalate, cetyl alcohol, chitosan, ethylcellulose, fructose, gelatin, glycerin, glyceryl behenate, glyceryl palmitostearate, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, hypromellose phthalate, isomalt, glucose, maltitol, maltodextrin, methylcellulose, microcrystalline wax, paraffin, poloxamer, polydextrose, polyethylene glycol, polyvinyl acetate phthalate, polyvinyl alcohol, povidone, shellac, sucrose, titanium oxide, tributyl citrate, triethyl citrate, vanillin, xylitol, zein, talc, triethanolamine, ammonium alginate, chlorpheniramine maleate, copovidone, ethyl lactate, and the like.

Wetting agents include, for example, polyethylene glycol, docusate sodium, sodium lauryl sulfate, polyethylene oxide, lecithin, poloxamer, and povidone, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, hypromellose, poloxamer, polythethylene alkyl ethers, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxoethylene sorbitan fatty acid esters, polyoxyethylene stearates, sodium lauryl sulfate, sorbitan esters, benzyl alcohol, benzyl benzoate, cetylpyridinium chloride, cyclodextrins, glycerin monostearate, lecithin, meglumine, poloxamer, povidone, sodium bicarbonate, stearic acid, sulfobutylether beta-cyclodextrin, and the like.

Of interest in certain embodiments are anti-adhesion layers. In these embodiments, materials of interest for use in anti-adhesion layers include, but are not limited to: ethyl cellulose, microcrystalline cellulose, cellulose derivative, silicates, e.g., magnesium silicates or aluminum silicates, oxides, e.g., titanium oxide, etc. As indicated above, mixtures of the above materials or materials analogous thereto may be employed.

Additional materials of interest that may be employed for the various components of the invention include, but are not limited to, those materials described in U.S. Pat. No. 6,685, 962, the disclosure of which material is herein incorporated by reference.

The identifiers of the invention may be fabricated using any convenient protocol. In certain embodiments, the signal amplification element is made of polymeric materials which are fabricated via a suitable protocol, such as solvent cast, extrusion, molding, micromachining, and the like. In certain embodiments, the signal amplification element is fabricated from compressed materials, e.g., via a tablet fabrication protocol. In certain embodiments, the signal amplification element is fabricated from multiple layers, e.g., via a lamination protocol.

One protocol for fabricating identifiers is shown schematically in FIG. 6. The schematic of FIG. 6 provides a process flow schematic for fabricating an identifier 60. In FIG. 6, the integrated circuit/electrode structure made up of integrated circuit 62, bottom electrode 66 and top electrode 64 (collectively referred to as 63) is first provided, e.g., using planar processing techniques. Next, a disc 68 of insulative material is provided, where a hole 67 for the element 63 is punched in the middle of the disc. Element 63 is then placed in hole 67 to provide the final identifier 60. Attachment of element 63 to insulative material 68 may be done with adhesive (such as an edible adhesive) or heat treatment, or other convenient protocol.

An alternative protocol for fabricating an identifier according to an embodiment of the invention is shown in FIG. 7. In this embodiment, integrated circuit 72 is first provided. Next, insulative material 78 is deposited around the integrated circuit 72. The upper surface of the resultant structure is then planarized as shown in the FIG. 7 to

14

produce a planar upper surface 77. A metal layer 74 is then deposited on the planar upper surface 77 to produce an upper electrode. Although not shown in FIG. 7, a removable backing may be employed in certain instances. For example, to produce the initial structure shown in FIG. 7, a removable backing may first be provided onto which the integrated circuit 72 is placed. The insulative material may then be deposited onto the removable backing, around the integrated circuit. Instead of a removable backing, the initial support may be the bottom electrode. For example, to fabricate the structure shown in FIG. 3, initial bottom electrode 36 may first be provided. Next, integrated circuit may be positioned in the center of the electrode 36. Insulative material 38 may then be deposited onto the bottom electrode 36 and around integrated circuit 32 to provide the structure shown in FIG. 3.

Another protocol for fabricating identifiers according to the invention is to use a mechanical approach in which two or more signal amplification components are prefabricated and then combined with identifier, e.g., by pressing them around an identifier, to produce an identifier with a signal amplification element. An example of such an embodiment is illustrated in FIGS. 8A and 8B, which illustrate a table solid dosage form of an ingestible event marker, where the IEM includes an identifier and a tablet component. In FIG. 8A, signal amplification element components 81 and 82 are pressed together around IC component 83 to produce identifier 80. The components 81 and 82 may be part of the tablet component, such that the signal amplification element is integral with the tablet component, and in certain embodiments components 81 and 82 may be the sole portions of the tablet component of the IEM. Each of the signal amplification element components 81 and 82 are pre-fabricated components, e.g., pressed components. Each of these components is made up of an insulative material, e.g., as described above. In fabricating identifiers according to these embodiments, the signal amplification element components may be held together using any convenient approach. One type of approach of interest is to employ an adhesive, i.e., glue. In FIG. 8A, components 81 and 82 have a staggered or stepped configuration, as illustrated. Other configurations are also within the scope of the invention, e.g., a linear configuration as illustrated in FIG. 8B.

FIG. 8C provides an illustration of yet another fabrication protocol suitable for fabricating an IEM that is in a tablet configuration. In FIG. 8C, compressed tablet 84 is first provided, where the tablet may or may include an active agent, e.g., as described above. Signal amplification element 85 is placed on top of tablet 84 to provide cavity 86. In this step, the signal amplification element 85 may be one that has been coated onto the tablet, or may have been prefabricated and then positioned on the upper surface of the tablet 84. The signal amplification element 85 may have a hole that corresponds to the tablet 81 already present before placement, or the hole may be provided following placement, e.g., via punching or laser drilling, to provide for cavity 86. Next, IC component 87 is positioned in cavity 86 to produce final IEM 80. IC may be held in cavity 86 with glue, where desired.

Yet another embodiment is shown in FIG. 8D, where identifier 80 is made up of IC 87 stably positioned in the center of donut-shaped tablet 88, where the donut-shaped tablet 88 serves as the signal amplification element, and optionally may serve as a depot for active agent, as desired. The donut-shaped tablet 88 may be formulated to provide for desired dissolution characteristics, e.g., be fabricated for

15

slow dissolution. FIG. 8D is another embodiment in which the signal amplification is the table component of the IEM.

One embodiment of interest in which the identifiers may be found is in a "gel cap" formulation, in which an active agent is present in a gel cap carrier and the identifier is part of the gel cap carrier. Such embodiments are shown in FIGS. 9A and 9B. For fabrication of gel cap formulations, a variety of different starting materials may be employed. For example, the integrated circuit may initially be by itself, or it can have battery electrodes already on it, and/or the signal amplification element already present, where these different initial starting configurations are then combined with the gel cap structure to produce the desired formulation. In making gel cap formulations, a holder may be employed, around which structure the gel cap is produced, such that the holder serves as a support for the integrated circuit during fabrication and as a mold that the gel cap can form around.

In one embodiment as shown in FIGS. 9A and 9B, initially an integrated circuit with both battery materials already deposited on it is employed, and this initial structure is present on a holder. As shown in FIG. 9A, an integrated circuit 92 with upper and lower electrodes already present thereon (94 and 96) is provided on holder 91. In FIG. 9B, the gel cap material 97 is deposited around the circuit/holder, where the gel cap material where the material may be deposited in a manner that it does not cover the top surface of the upper electrode (see FIG. 9B, or a hole can be produced in the deposited material (e.g., via laser drilling) to expose the top surface of the electrode. In these embodiments, the gel cap material may serve as the signal amplification element. Following setting of the gel cap material, holder 71 may be removed and the resultant structure, filled with a convenient active agent composition to produce a final gel cap formulation that includes an identifier.

In alternative embodiments, the signal amplification element is fabricated from a material that is distinct from the material of the gel cap. An example of such an embodiment is depicted in FIGS. 9C and 9D. In FIG. 9C, the holder 91 has positioned on its upper surface a structure that includes the integrated circuit 92, lower electrode 96 and upper electrode 94. Also shown is a signal amplification element 98. In FIG. 9D, the gel cap is deposited around the structure shown in FIG. 9C, e.g., in a manner that either leaves the top exposed, or where a hole is drilled to open it up after the gel cap has been placed on the structure, e.g., described above.

Another variation of the above protocol is provided in FIGS. 9E and 9F. As shown in FIG. 9E, an integrated circuit 92 with a lower electrode 96 already present thereon is provided on holder 91. In FIG. 9F, the gel cap material 97 is deposited around the circuit/holder, where the gel cap material is deposited in a manner that it does not cover the top surface of the lower electrode and integrated circuit. Next, a pre-made structure of the upper electrode 94 and signal amplification element 98 with an appropriate space 95 for the integrated circuit (collectively labeled 99) is positioned on top of the integrated circuit to finalize the gel cap structure.

Again, following fabrication of the gel cap structure as described above, the structure may be filled with appropriate active agent material as desired to produce the final formulation.

Yet another protocol for producing an IEM configured for use in a capsule format is illustrated in FIGS. 10A and 10B. In FIG. 10A, IEM 100 includes capsule cap 101 and capsule body 102. In capsule cap 101, identifier 103 is present, which is made up of IC component 104 and skirt component 105. FIG. 10B provides an illustration of one protocol for

16

fabricating the IEM shown in FIG. 10A. In the embodiment illustrated in FIG. 10B, skirt component 105 is provided in prefabricated capsule cap 101. Next, a hole 106 is provided in skirt component 105, e.g., via punching or laser drilling. Following this step, IC component 104 is placed in hole 106 to produce identifier 103, where the IC component 104 may be held in place with an adhesive, as desired. FIG. 10A provides an illustration of an embodiment where the signal amplification element is integral with the capsule component of capsule IEM 100. In yet other embodiments, the capsule component and the signal amplification element may be the same structure.

As reviewed above, the circuitry that drives the identifier may include a number of different functional blocks, e.g., signal generation blocks, activation blocks, transmitter blocks, a power source, etc. In certain embodiments, these functional blocks are provided in the form of an integrated circuit, where the integrated circuits of these embodiments include a number of distinct functional blocks, i.e., modules, where the functional blocks are all present in a single integrated circuit on an intraluminal-sized support. By single integrated circuit is meant a single circuit structure that includes all of the different functional blocks. As such, the integrated circuit is a monolithic integrated circuit (also known as IC, microcircuit, microchip, silicon chip, computer chip or chip) that is a miniaturized electronic circuit (which may include semiconductor devices, as well as passive components) that has been manufactured in the surface of a thin substrate of semiconductor material. The integrated circuits of certain embodiments of the present invention are distinct from hybrid integrated circuits, which are miniaturized electronic circuits constructed of individual semiconductor devices, as well as passive components, bonded to a substrate or circuit board.

The support with which the circuit is associated, e.g., by being present on surface of the support or integrated, at least partially, inside of the support, may be any convenient support, and may be rigid or flexible as desired. As the support is intraluminal-sized, its dimensions are such that it can be positioned inside of a physiological lumen, e.g., inside of a vessel, such as a cardiac vessel, e.g., a vein or artery. In certain embodiments, the intraluminal-sized integrated circuits have a size (e.g., in terms of surface area of largest surface) of between about 0.05 mm² and about 5 mm², such as between about 1.125 mm² and about 2.5 mm², and including about 1.5 mm². The supports of the integrated circuits can have a variety of different shapes, such as square, rectangle, oval, and hexagon, irregular, etc.

FIG. 11 shows the detail of one implementation of an electronic circuit that can be employed in an identifier according to the present invention. On the left side are the two battery electrodes, metal 1 and metal 2 (112 and 113). These metals, when in contact with an electrolyte (produced upon contact with target site fluid, either alone or in combination with dried conductive medium precursor, as reviewed above), form a battery that provides power to an oscillator 111, in this case shown as a schematic. The metal 1 112 provides a low voltage, (ground) to the oscillator 111. Metal 2 113 provides a high voltage (V_{high}) to the oscillator 111. As the oscillator 111 becomes operative, it generates a clock signal 118 and an inverted clock signal 119, which are opposites of each other. These two clock signals enter the counter 114 which simply counts the number of clock cycles and stores the count in a number of registers. In the example shown here, an 8 bit counter is employed. Thus, the output of counter 114 begins with a value of "00000000," changes to "00000001" at the first clock cycle, and continues up to

"11111111." The 8-bit output of counter **114** is coupled to the input of an address multiplexer (mux) **115**. In one embodiment, mux **115** contains an address interpreter, which can be hard-wired in the circuit, and generates a control voltage to control the oscillator **111**. Mux **115** uses the output of counter **114** to reproduce the address in a serial bit stream, which is further fed to the signal-transmission driving circuit. Mux **115** can also be used to control the duty-cycle of the signal transmission. In one embodiment, mux **115** turns on signal transmission only one sixteenth of the time, using the clock counts generated by counter **114**. Such a low duty cycle conserves power and also allows other devices to transmit without jamming their signals. The address of a given chip can be 8 bits, 16 bits or 32 bits. In certain embodiments, more than 8 bits will be used in a product, e.g., where there are so many different types of items to be identified, such as pharmaceuticals, where it is desired that each item have its own specific address.

The present invention also allows the possibility that, where appropriate, each pharmaceutical batch can be provided with a batch specific address. This allows identification of where the pill was made, when the pill was made, and in what batch it was made. In some cases, each pill will have a unique identifier. This would be particularly useful when drugs are more likely to be subsequently stolen or used illicitly, and thus should be tracked, or where questions of contamination may arise.

According to one embodiment, mux **115** produces a control voltage, which encodes the address serially and is used to vary the output frequency of oscillator **111**. By example, when the control voltage is low, that is, when the serial address bit is at a 0, a 1 megahertz signal is generated by the oscillator. When the control voltage is high, that is, when the address bit is a 1, a 2 megahertz signal is generated the oscillator. Alternately, this can be 10 megahertz and 20 megahertz, or a phase shift keying approach where the device is limited to modulating the phase. The purpose of mux **115** is to control the frequency of the oscillator or an AC alternative embodiment of the amplified signal of oscillation.

The outputs of mux **115** are coupled to electrode drive **116** which can drive the electrodes to impose a differential potential to the solution, drive an oscillating current through a coil to generate a magnetic signal, or drive a single electrode to push or pull charge to or from the solution.

In this manner, the device broadcasts the sequence of 0's and 1's which constitute the address stored in mux **115**. That address would be broadcast repeatedly, and would continue broadcasting until metal 1 or metal 2 (**112** and **113**) is consumed and dissolved in the solution, or when the battery no longer operates. The signal that is broadcasted is enhanced by the presence of a signal amplification element, not shown, as described above.

Other configurations for the circuitry are of course possible. Other configurations of interest include, but are not limited to, those described in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled "Pharma-Informatics System"; PCT application serial no. PCT/US2007/022257 filed on Oct. 17, 2007 and titled "In-vivo Low Voltage Oscillator for Medical Devices"; PCT application serial no. PCT/US 2007/82563 filed on Oct. 25, 2007 and titled "Controlled Activation Ingestible Identifier"; U.S. patent application Ser. No. 11/776,480 filed Jul. 11, 2007 entitled "Acoustic Pharma Informatics System"; and PCT application serial no. PCT/US2008/52845 filed on Feb. 1, 2008 and titled "Ingestible Event Marker Systems";

the disclosures of which applications (and particularly signal generation components thereof) are herein incorporated by reference.

As indicated above, various components of the identifiers may be fabricated using any convenient processing technology. In certain embodiments, planar processing protocols are employed, e.g., to fabricate power sources having surface electrodes, where the surface electrodes include at least an anode and cathode at least partially on the same surface of a circuitry support element. In some embodiments, the power source can comprise a battery. In certain embodiments, planar processing protocols are employed in a wafer bonding protocol to produce a battery source. Planar processing techniques, such as Micro-Electro-Mechanical Systems (MEMS) fabrication techniques, including surface micromachining and bulk micromachining techniques, may be employed. Deposition techniques that may be employed in certain embodiments of fabricating the structures include, but are not limited to: electrodeposition (e.g., electroplating), cathodic arc deposition, plasma spray, sputtering, e-beam evaporation, physical vapor deposition, chemical vapor deposition, plasma enhanced chemical vapor deposition, etc. Material removal techniques included, but are not limited to: reactive ion etching, anisotropic chemical etching, isotropic chemical etching, planarization, e.g., via chemical mechanical polishing, laser ablation, electronic discharge machining (EDM), etc. Also of interest are lithographic protocols. Of interest in certain embodiments is the use of planar processing protocols, in which structures are built up and/or removed from a surface or surfaces of an initially planar substrate using a variety of different material removal and deposition protocols applied to the substrate in a sequential manner. Illustrative fabrication methods of interest are described in greater detail in copending PCT application serial no. PCT/US2006/016370; the disclosure of which is herein incorporated by reference.

Optional Physiologically Acceptable Carrier Component

Identifiers of the invention that include virtual dipole signal amplification elements as described above may be present in (i.e., combined with) a physiologically acceptable carrier component, e.g., a composition or vehicle that aids in ingestion of the identifier and/or protects the identifier until it reaches the target site of interest. By physiologically acceptable carrier component" is meant a composition, which may be a solid or fluid (e.g., liquid), which has is ingestible.

Common carriers and excipients, such as corn starch or gelatin, lactose, dextrose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid are of interest. Disintegrators commonly used in the formulations of the invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.

A liquid composition may comprise a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example, ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, with a suspending agent, preservative, surfactant, wetting agent, flavoring or coloring agent. Alternatively, a liquid formulation can be prepared from a reconstitutable powder. For example, a powder containing active compound, suspending agent, sucrose and a sweetener can be reconstituted with water to form a suspension; and a syrup can be prepared from a powder containing active ingredient, sucrose and a sweetener.

A composition in the form of a tablet or pill can be prepared using any suitable pharmaceutical carrier(s) rou-

tinely used for preparing solid compositions. Examples of such carriers include magnesium stearate, starch, lactose, sucrose, microcrystalline cellulose and binders, for example, polyvinylpyrrolidone. The tablet can also be provided with a color film coating, or color included as part of the carrier(s). In addition, active compound can be formulated in a controlled release dosage form as a tablet comprising a hydrophilic or hydrophobic matrix.

"Controlled release", "sustained release", and similar terms are used to denote a mode of active agent delivery that occurs when the active agent is released from the delivery vehicle at an ascertainable and controllable rate over a period of time, rather than dispersed immediately upon application or injection. Controlled or sustained release may extend for hours, days or months, and may vary as a function of numerous factors. For the pharmaceutical composition of the present invention, the rate of release will depend on the type of the excipient selected and the concentration of the excipient in the composition. Another determinant of the rate of release is the rate of hydrolysis of the linkages between and within the units of the polyorthoester. The rate of hydrolysis in turn may be controlled by the composition of the polyorthoester and the number of hydrolysable bonds in the polyorthoester. Other factors determining the rate of release of an active agent from the present pharmaceutical composition include particle size, acidity of the medium (either internal or external to the matrix) and physical and chemical properties of the active agent in the matrix.

A composition in the form of a capsule can be prepared using routine encapsulation procedures, for example, by incorporation of active compound and excipients into a hard gelatin capsule. Alternatively, a semi-solid matrix of active compound and high molecular weight polyethylene glycol can be prepared and filled into a hard gelatin capsule; or a solution of active compound in polyethylene glycol or a suspension in edible oil, for example, liquid paraffin or fractionated coconut oil can be prepared and filled into a soft gelatin capsule.

Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, poly-vinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose. Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.

Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. Additionally, it may be desirable to add a coloring agent to make the dosage form more attractive in appearance or to help identify the product.

Other components suitable for use in the formulations of the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985).

Optional Active Agent

In certain embodiments, the identifier is not associated with a pharmaceutically active agent. As such, the identifier, and any carrier or other component that make up the ingestible event marker, do not include an active agent.

In yet other embodiments, the identifier is associated with an active agent, e.g., where the active agent is present in the carrier composition that includes the identifier. In some embodiments, the signal generation element can be stably associated with an active agent. By "active agent/carrier component" is meant a composition, which may be a solid or fluid (e.g., liquid), which has an amount of active agent, e.g., a dosage, present in a pharmaceutically acceptable

carrier. The active agent/carrier component may be referred to as a "dosage formulation."

"Active agent" includes any compound or mixture of compounds which produces a physiological result, e.g., a beneficial or useful result, upon contact with a living organism, e.g., a mammal, such as a human. Active agents are distinguishable from such components as vehicles, carriers, diluents, lubricants, binders and other formulating aids, and encapsulating or otherwise protective components. The active agent may be any molecule, as well as binding portion or fragment thereof, that is capable of modulating a biological process in a living subject. In certain embodiments, the active agent may be a substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication. In certain embodiments, the active agent may be a chemical substance, such as a narcotic or hallucinogen, which affects the central nervous system and causes changes in behavior.

The active agent (i.e., drug) is capable of interacting with a target in a living subject. The target may be a number of different types of naturally occurring structures, where targets of interest include both intracellular and extracellular targets. Such targets may be proteins, phospholipids, nucleic acids and the like, where proteins are of particular interest. Specific proteinaceous targets of interest include, without limitation, enzymes, e.g., kinases, phosphatases, reductases, cyclooxygenases, proteases and the like, targets comprising domains involved in protein-protein interactions, such as the SH2, SH3, PTB and PDZ domains, structural proteins, e.g., actin, tubulin, etc., membrane receptors, immunoglobulins, e.g., IgE, cell adhesion receptors, such as integrins, etc., ion channels, transmembrane pumps, transcription factors, signaling proteins, and the like.

The active agent (i.e., drug) may include one or more functional groups necessary for structural interaction with the target, e.g., groups necessary for hydrophobic, hydrophilic, electrostatic or even covalent interactions, depending on the particular drug and its intended target. Where the target is a protein, the drug moiety may include functional groups necessary for structural interaction with proteins, such as hydrogen bonding, hydrophobic-hydrophobic interactions, electrostatic interactions, etc., and may include at least an amine, amide, sulfhydryl, carbonyl, hydroxyl or carboxyl group, such as at least two of the functional chemical groups.

Drugs of interest may include cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Also of interest as drug moieties are structures found among biomolecules, including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Such compounds may be screened to identify those of interest, where a variety of different screening protocols are known in the art.

The active agent may be derived from a naturally occurring or synthetic compound that may be obtained from a wide variety of sources, including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including the preparation of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial

libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.

As such, the active agent may be obtained from a library of naturally occurring or synthetic molecules, including a library of compounds produced through combinatorial means, i.e., a compound diversity combinatorial library. When obtained from such libraries, the drug moiety employed will have demonstrated some desirable activity in an appropriate screening assay for the activity. Combinatorial libraries, as well as methods for producing and screening such libraries, are known in the art and described in U.S. Pat. Nos. 5,741,713; 5,734,018; 5,731,423; 5,721,099; 5,708,153; 5,698,673; 5,688,997; 5,688,696; 5,684,711; 5,641,862; 5,639,603; 5,593,853; 5,574,656; 5,571,698; 5,565,324; 5,549,974; 5,545,568; 5,541,061; 5,525,735; 5,463,564; 5,440,016; 5,438,119; 5,223,409, the disclosures of which are herein incorporated by reference.

Broad categories of active agents of interest include, but are not limited to: cardiovascular agents; pain-relief agents, e.g., analgesics, anesthetics, anti-inflammatory agents, etc.; nerve-acting agents; chemotherapeutic (e.g., anti-neoplastic) agents; etc.

A variety of manufacturing protocols may be employed to produce compositions as described above, e.g., where an identifier is present in pharmaceutically acceptable carrier or vehicle, where the carrier or vehicle may further include one or more active agents.

In manufacturing such compositions, an identifier is stably associated with the pharmaceutical dosage form in some manner. By stably associated is meant that the identifier and the dosage form do not separate from each other, at least until administered to the subject in need thereof, e.g., by ingestion. The identifier may be stably associated with the pharmaceutical carrier/active agent component of the composition in a number of different ways.

In certain embodiments, where the carrier/active agent component is a solid structure, e.g., such as a tablet or pill, the carrier/active agent component is produced in a manner that provides a cavity for the identifier. The identifier is then placed into the cavity and the cavity sealed, e.g., with a biocompatible material, to produce the final composition. For example, in certain embodiments a tablet is produced with a die that includes a feature which produces a cavity in the resultant compressed tablet. The identifier is placed into the cavity and the cavity sealed to produce the final tablet.

In a variation of this embodiment, the tablet is compressed with a removable element, e.g., in the shape of a rod or other convenient shape. The removable element is then removed to produce a cavity in the tablet. The identifier is placed into the cavity and the cavity sealed to produce the final tablet.

In another variation of this embodiment, a tablet without any cavity is first produced and then a cavity is produced in the tablet, e.g., by laser drilling. The identifier is placed into the cavity and the cavity sealed to produce the final tablet.

In yet other embodiments, a tablet is produced by combining the identifier with subparts of the tablet, where the subparts may be pre-made subparts or manufactured sequentially. For example, in certain embodiments tablets are produced by first making a bottom half of the tablet, placing the signal generation element on a location of the bottom half of the tablet, and then placing top portion of the tablet over the bottom half and signal generation element to produce the final desired composition.

In certain embodiments, a tablet is produced around an identifier such that the identifier is located inside of the

produced tablet. For example, an identifier, which may or may not be encapsulated in a biocompatible compliant material, e.g., gelatin (to protect the signal generation element), is combined with carrier/active agent precursor, e.g., powder, and compressed or molded into a tablet in a manner such that the identifier is located at an internal position of the tablet. Instead of molding or compressing, the carrier/active agent component is, in certain embodiments, sprayed onto an identifier in a manner that builds up the tablet structure.

In yet another embodiment, the active agent/carrier component precursor may be a liquid formulation which is combined with the identifier and then solidified to produce the final composition.

In yet other embodiments, pre-made tablets may be fitted with an identifier by stably attaching an identifier to the tablet.

Of interest are protocols that do not alter the properties of the tablet, e.g., dissolution etc. For example, a gelatin element that snap fits onto one end of a tablet and has an identifier integrated with it is employed in certain embodiments. The gelatin element is colored in certain embodiments to readily identify tablets that have been fitted with the signal generation element.

Where the composition has an active agent/carrier composition filled capsule configuration, e.g., such as a gelatin capsule filled configuration, an identifier may be integrated with a capsule component, e.g., top or bottom capsule, and the capsule filled with the active agent/carrier composition to produce the final composition.

The above reviewed methods of manufacture are merely illustrative of the variety of different ways in which the compositions of the invention may be manufactured.

In certain embodiments, the identifiers are disrupted upon administration to a subject. As such, in certain embodiments, the compositions are physically broken, e.g., dissolved, degraded, eroded, etc., following delivery to a body, e.g., via ingestion, injection, etc. The compositions of these embodiments are distinguished from devices that are configured to be ingested and survive transit through the gastrointestinal tract substantially, if not completely, intact.

Systems

Also provided are systems that include the subject compositions. Systems of the subject invention include, in certain embodiments, an ingestible event marker comprising one or more devices that include a virtual dipole signal transmission element of the invention, e.g., an identifier as reviewed above, as well as a signal detection component, e.g., in the form of a receiver. The signal detection component may vary significantly depending on the nature of the signal that is generated by the signal generation element of the composition, e.g., as reviewed above.

Signal receivers of systems of embodiments of the invention are those that are configured to receive a signal from an identifier, e.g., to receive a signal emitted by an identifier upon contact of the identifier with the target physiological site following ingestion of the identifier. The signal receiver may vary significantly depending on the nature of the signal that is generated by the signal generation element, e.g., as reviewed below. As such, the signal receiver may be configured to receive a variety of different types of signals, including but not limited to: RF signals, magnetic signals, conductive (near field) signals, acoustic signals, etc., as indicated above. In certain embodiments, the receiver is configured to receive a signal conductively from another component, e.g., the identifier, such that the two components use the body of the patient as a communication medium. As such, the signal that is transferred between identifier and the

receiver travels through the body, and requires the body as the conduction medium. The identifier emitted signal may be transmitted through and received from the skin and other body tissues of the subject body in the form of electrical alternating current (a.c.) voltage signals that are conducted through the body tissues. As a result, such embodiments do not require any additional cable or hard wire connection, or even a radio link connection for transmitting the sensor data from the autonomous sensor units to the central transmitting and receiving unit and other components of the system, since the sensor data are directly exchanged via the skin and other body tissues of the subject. This communication protocol has the advantage that the receivers may be adaptably arranged at any desired location on the body of the subject, whereby the receivers are automatically connected to the required electrical conductor for achieving the signal transmission, i.e., the signal transmission is carried out through the electrical conductor provided by the skin and other body tissues of the subject. In certain embodiments, the signal detection component is one that is activated upon detection of a signal emitted from an identifier. In certain embodiments, the signal receiver is capable of (i.e., configured to) simultaneously detecting multiple different signals, e.g., 2 or more, 5 or more, 10 or more, etc.

The signal receiver may include a variety of different types of signal receiver elements, where the nature of the receiver element necessarily varies depending on the nature of the signal produced by the signal generation element. In certain embodiments, the signal receiver may include one or more electrodes (e.g., 2 or more electrodes, 3 or more electrodes, and/or includes multiple, e.g., 2 or more, 3 or more, 4 or more pairs of electrodes, etc.) for detecting signal emitted by the signal generation element. In certain embodiments, the receiver device will be provided with two electrodes that are dispersed at a distance, e.g., a distance that allows the electrodes to detect a differential voltage. This distance may vary, and in certain embodiments ranges from about 0.1 to about 5 cm, such as from about 0.5 to about 2.5 cm, e.g., about 1 cm. In an alternative embodiment, a receiver that utilizes a single electrode is employed. In certain embodiments, the signal detection component may include one or more coils for detecting signal emitted by the signal generation element. In certain embodiments, the signal detection component includes an acoustic detection element for detecting signal emitted by the signal generation element. In certain embodiments, multiple pairs of electrodes (e.g., as reviewed above) are provided, for example to increase detection probability of the signal.

The signal receivers of interest include both external and implantable signal receivers. In external embodiments, the signal receiver is ex vivo, by which is meant that the receiver is present outside of the body during use. Where the receiver is implanted, the signal receiver is in vivo. The signal receiver is configured to be stably associated with the body, e.g., either in vivo or ex vivo, at least during the time that it receives the emitted signal from the IEM.

Signal receivers of interest include, but are not limited to, those receivers disclosed in: PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled "Pharma-Informatics System"; and PCT application serial no. PCT/US2008/52845 filed on Feb. 1, 2008 and titled "Ingestible Event Marker Systems"; the disclosures of which applications (and particularly signal receiver components thereof) are herein incorporated by reference.

In certain embodiments, the signal receiver is configured to provide data of a received signal to a location external to said subject. For example, the signal receiver may be

configured to provide data to an external data receiver, e.g., which may be in the form of a monitor (such as a bedside monitor), a computer (e.g., PC or MAC), a personal digital assistant (PDA), phone, messaging device, smart phone, etc. In one embodiment, if a signal receiver failed to detect a signal indicating that a pill had been ingested, the signal receiver could transmit a reminder to take the pill to the subject's PDA or smart phone, which could then provide a prompt to the user to take the medication, e.g., a display or alarm on the PDA, by receiving a phone call on the smart phone (e.g., a recorded message) etc. The signal receiver may be configured to retransmit data of a received signal to the location external to said subject. Alternatively, the signal receiver according may be configured to be interrogated by an external interrogation device to provide data of a received signal to an external location.

As such, in certain embodiments the systems include an external device which is distinct from the receiver (which may be implanted or topically applied in certain embodiments), where this external device provides a number of functionalities. Such an apparatus can include the capacity to provide feedback and appropriate clinical regulation to the patient. Such a device can take any of a number of forms. By example, the device can be configured to sit on the bed next to the patient, e.g., a bedside monitor. Other formats include, but are not limited to, PDAs, smart phones, home computers, etc. The device can read out the information described in more detail in other sections of the subject patent application, both from pharmaceutical ingestion reporting and from physiological sensing devices, such as is produced internally by a pacemaker device or a dedicated implant for detection of the pill. The purpose of the external apparatus is to get the data out of the patient and into an external device. One feature of the external apparatus is its ability to provide pharmacologic and physiologic information in a form that can be transmitted through a transmission medium, such as a telephone line, to a remote location such as a clinician or to a central monitoring agency.

Methods

Aspects of the invention further include methods of using in-body devices that include virtual dipole signal transmission elements of the invention. Generally, methods of the invention will include placing the in-body device in some manner in the body of the subject, e.g., by implanting the device in a subject, by ingesting the device, etc. The devices may be employed with a variety of subjects. Generally such subjects are "mammals" or "mammalian," where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In certain embodiments, the subjects will be humans. Following placement of the devices in the body of a subject, the devices are employed for a variety of purposes, e.g., to sense one or more physiological parameters, to deliver one or more therapies, to mark a personal event of interest, etc.

In certain embodiments, the in-body devices are ingestible devices, where the virtual dipole signal transmission element is part of an identifier of the device. In such embodiments, the identifier is ingested and a signal emitted by the identifier is detected, e.g., with a receiver as described above. Such methods are further described in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled "Pharma-Informatics System"; and PCT application serial no. PCT/US 2008/52845 filed on Feb. 1, 2008 and titled "Ingestible Event Marker Systems"; the disclo-

tures of which applications (and particularly signal receiver components thereof) are herein incorporated by reference. Utility

Devices that include the antennas of the invention may be employed in a variety of different applications, including both therapeutic and non-therapeutic applications. Specific applications of interest include, but are not limited to: those applications described in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled "Pharma-Informatics System"; and PCT application serial no. PCT/US 2008/52845 filed on Feb. 1, 2008 and titled "Ingestible Event Marker Systems"; the disclosures of which applications (and particularly signal receiver components thereof) are herein incorporated by reference.

IEM in body devices of the invention may be employed in a variety of different applications, which applications may be both medical and non-medical in nature. Different illustrative applications are now reviewed in greater detail below.

Certain applications involve the use of IEMs by themselves to mark a personal event of interest, e.g., onset of a physiological parameter (such as a symptom(s) of interest), onset of an activity, etc. For example, in certain embodiments, event markers are employed to mark the onset of a symptom of interest. In such instances, when an individual becomes aware of a symptom of interest, e.g., begins to feel flushed, nauseous, excited, etc., e.g., the individual may ingest an IEM to mark the occurrence of the symptom of interest. For example, the patient may begin to not feel well, and ingest an event marker in response to this ill feeling. Upon ingestion, the marker sends a signal to a receiver, which may then record receipt of the signal for further use, e.g., to combine with physiological data, etc. In certain embodiments, the received signal is employed to provide context for any physiological data that is obtained from the patient, e.g., by sensors on the receiver, from an implantable recorder, etc.

Another symptom of interest is pain. In these embodiments, the ingestible event marker may be employed as a pain marker. For example, in the case where a patient is being monitored for pain, if a patient feels no pain, the patient may ingest a first type of marker. If the patient feels pain, the patient may ingest a second type of marker. Different types of markers may be differentiated, such as color coded, where desired, to assist in their identification and proper use by the patient. For example, markers to be ingested when the patient does not feel pain may be color coded blue, while markers that are to be ingested when the patient does have pain may be color coded yellow. In another embodiment, instead of having different types of markers, a protocol may be employed in which the number of markers ingested, and therefore the signal obtained, e.g., from a single marker or two or more markers, is employed to denote a scale of the symptom of interest, such as pain. For example, if an individual is having intense pain, the individual takes four of the positive pain marker pills at the same time, while in response to mild pain the individual may take only one marker.

In such embodiments, the onset of the symptom of interest, as marked by the ingestion of the event marker and detection of the signal by the receiver, may be employed as relevant point at which to begin recording one or more physiological parameters of interest, e.g., by using an implantable physiological monitor. In these instances, the emitted signal from the marker is received by the receiver, which then causes a physiological parameter recorder (such as a Reveal® Plus Insertable Loop Recorder (ILR), Medtronic Corporation) to begin recording data and saving

the data, e.g., for later use. For example, an implantable physiological parameter recorder may have only a limited possible amount of time for recording (such as 42 minutes). In such situations, the data may be automatically overwritten unless somehow flagged or marked for protection. In the present methods, an IEM may be ingested to mark the onset of a symptom of interest, as perceived by the patient, and the receiver upon receipt of the signal may act with the recorder to protect the data obtained around the time of the signal (after, or even some time before) to be protected and not overwritten. The system may be further configured to work in response not only to the ingestion of the event marker, but also in response to physiological sensed parameters, e.g., pH. As such, the methods find use as an event recorder in terms of flagging a diagnostic stream of information, and protecting it from being overwritten, so a physician can look at it at a later date.

In certain embodiments, the event marker provides the context for interpreting a given set of physiological data at a later time. For example, if one is employing an activity sensor and one co-administers an event marker with a particular drug, one can note any change in activity that is brought about by that drug. If a drop in activity is observed after a person takes both the event marker and a drug, the drop indicates the drug is probably causing the person to reduce their activity, e.g., by making them feel sleepy or actually causing them to fall asleep. Such data may be employed to adjust the dose of a drug or be the basis for a decision to switch to an alternative medication.

In certain embodiments the event marker is employed to construct a database of multiple events. Such a database may be employed to find commonality between the multiple marked events. Simple or complex protocols for finding commonality among multiple marked events may be employed. For example, multiple events may be averaged. Alternatively techniques such as impulse response theory may be employed, where such techniques provide information on what exactly are the common features in a set of multiple sensor streams that are tied to a particular event.

The IEM systems of the invention enable one to use subjective symptoms, such as "I'm feeling funny," to impart context and background to obtained objective measures of what is occurring physiologically. For example, if every time a subject felt abnormal they took an event marker, one could reference a database of the objective sensor data, and find common features in the database. Such an approach may be employed to discover the underlying causes of the subjective feeling. For example, such an approach may be employed to determine that every time a patient is feeling "funny", there is an associated change in their blood pressure, and the link between a subjective symptom and objective physiological data can be used in their diagnosis. As such, a generalizable event marker brings context to discrete data from any other source. Therefore, use of the oral medication event markers can provide context for any other associated health monitoring information or health event.

In certain embodiments, the event marker can be an alert marker, such that ingestion of the marker causes an alarm signal to be sent from the patient, e.g., indicating that the patient needs medical assistance. For example, when a patient feels an onset of a symptom of interest, such as chest pain, shortness of breath, etc., the patient may ingest an event marker. The signal emitted from the event marker may be received by the receiver, which may then cause an alarm to be generated and distributed to a medical professional.

In certain embodiments, the event marker is employed to instigate or start a therapeutic action, e.g., activate an

implantable pulse generator to deliver electrical therapy, activate an implanted drug delivery device to administer a dosage of drug, activate a physiological sensor to begin acquiring data, etc. For example, where a patient has a neural stimulator for treating migraines, upon perception of the onset of aura, the patient could ingest an IEM. The emitted signal would then activate neural stimulator into stimulus mode, and thereby cause the implant to deliver therapy. Alternatively, if one has an implanted drug delivery device, e.g., a device that delivers an oncotic agent, ingestion of the IEM could cause the implanted device to deliver the active agent.

In certain embodiments, the event marker is employed to deliver information to an implanted medical device in the patient. For example, an ingestible event marker may send a signal that includes updated data for an implanted medical device, such as firmware upgrade data for an implantable pulse generator, e.g., a pace maker. In such instances, the signal may include the upgrade code which is broadcast from the IEM conductively to the medical device, where upon receipt of the signal and code, the firmware of the medical device is upgraded.

Other applications where event markers may be employed by themselves is to mark or note the start of non-medical personal event, such as a commute time, the start of an exercise regimen, sleep time, smoking (e.g., so one can log how much one smokes) etc.

As indicated above, embodiments of the invention are characterized in that the event markers are co-ingested with another composition of matter, e.g., a pharmaceutical composition, food, etc, where the event marker may or may not be present in the same composition as the co-ingested matter. For example, the event markers may be employed to track ingesting a pharmaceutical agent, where one co-administers the marker with the drug of interest. Applications where co-administration of a drug and marker is of interest include, but are not limited to, clinical studies, titration of medicine, e.g., blood pressure medicine, etc. Where desired, the IEM could be provided as just another pill to indicate when a refill is needed from the pharmacy.

Instead of co-ingesting the event marker with another composition, e.g., a drug, food, etc., the marker and the other composition may be compounded together, e.g., by the end user. For example, an IEM in the form of a capsule can be opened by the end user and filled with a pharmaceutical composition. The resultant compounded capsule and active agent may then be ingested by the end user. Instead of an end user, the pharmacist or a health care provider may perform the compounding step.

In yet other embodiments, the marker is present already compounded with the other composition at the source of manufacture of the other composition, e.g., the manufacturer or producer of a pharmaceutical composition. An example of such compositions includes those described in PCT application serial no. PCT/US2006/016370; the disclosure of which is herein incorporated by reference.

In certain embodiments, the IEMs of the invention are employed to allow one to look at, on an individual basis, what a given result is with respect to what drugs an individual is taking versus their impact on indicators that correlate to the desired effect. For example, where a given patient is prescribed a regimen of multiple pharmaceutical agents and there are multiple different physiological parameters that are monitored as indicators of how the patient is responding to the prescribed therapeutic regimen, a given drug as marked by a given marker can be assessed in terms of its impact on one or more of the physiological parameters

of interest. Following this assessment, adjustments can be made accordingly. In this manner, automation may be employed to tailor therapies based on individual responses. For example, where a patient is undergoing oncotic therapy, the event marker can be used to provide real time context to obtained physiological parameter data. The resultant annotated real time data can be used to make decisions about whether or not to continue therapy, or change to a new therapy.

In certain embodiments, a dosing event (as marked by the IEM) is correlated with sensor data to develop a profile for how a given drug acts, e.g., in terms of a pharmacokinetic and/or pharmacodynamic model. Sensors are employed with the IEM marking of the dosing event to obtain a pharmacokinetic model. Once a pharmacokinetic model is derived, one can use the dosing event to drive that model and predict serum drug levels and response. One might find, as determined from various sensors, that a patient is not responding well to therapy at a particular time. One might look back at the pharmacokinetic model to find that the levels of the therapeutic drug in the blood are low when the patient is not responding well, based on symptoms and/or objective physiological data. This data can then be used to make a determination to increase the dosing frequency or increase the dose level at a given dosing event. The event marker can therefore provide a way to develop a pharmacokinetic and/or pharmacodynamic model and then apply it to optimize patient therapy.

Where the IEMs are co-administered with a pharmaceutical agent, e.g., as two separate compositions or a single composition (as described above), the systems of the invention, enable a dynamic feedback and treatment loop of tracking medication timing and levels, measuring the response to therapy, and recommending altered dosing based on the physiology and molecular profiles of individual patients. For example, a symptomatic heart failure patient takes multiple drugs daily, primarily with the goal of reducing the heart's workload and improving patient quality of life. Mainstays of therapy include angiotensin converting enzyme (ACE) inhibitors, β -blockers and diuretics. For pharmaceutical therapy to be effective, it is vital that patients adhere to their prescribed regimen, taking the required dose at the appropriate time. Multiple studies in the clinical literature demonstrate that more than 50% of Class II and III heart failure patients are not receiving guideline-recommended therapy, and, of those who are titrated appropriately, only 40-60% adhere to the regimen. With the subject systems, heart failure patients can be monitored for patient adherence to therapy, and adherence performance can be linked to key physiologic measurements, to facilitate the optimization of therapy by physicians.

In certain embodiments, the systems of the invention may be employed to obtain an aggregate of information that includes sensor data and administration data. For example, one can combine the heart rate, the respiration rate, multi-axis acceleration data, something about the fluid status, and something about temperature, and derive indices that will inform about the total activity of the subject, that can be used to generate a physiological index, such as an activity index. For instance, when there is a rise in temperature, heart rate goes up a bit, and respiration speeds up, which may be employed as an indication that the person is being active. By calibrating this, the amount of calories the person is burning at that instant could be determined. In another example, a particular rhythmic set of pulses or multi-axis acceleration data can indicate that a person is walking up a set of stairs, and from that one can infer how much energy they are using.

In another embodiment, body fat measurement (e.g. from impedance data) could be combined with an activity index generated from a combination of measured biomarkers to generate a physiological index useful for management of a weight loss or cardiovascular health program. This information can be combined with cardiac performance indicators to get a good picture of overall health, which can be combined with pharmaceutical therapy administration data.

In another embodiment, one might find for example that a particular pharmaceutical correlates with a small increase in body temperature, or a change in the electrocardiogram. One can develop a pharmacodynamic model for the metabolism of the drug, and use the information from the receiver to essentially fit the free parameters in that model to give much more accurate estimation of the levels actually present in the serum of the subject. This information could be fed back to dosing regimes. In another embodiment, one can combine information from a sensor that measures uterine contractions (e.g. with a strain gauge) and that also monitors fetal heart rate, for use as a high-risk pregnancy monitor.

In certain embodiments, the subject specific information that is collected using the systems of the invention may be transmitted to a location where it is combined with data from one or more additional individuals to provide a collection of data which is a composite of data collected from 2 or more, e.g., 5 or more, 10 or more, 25 or more, 50 or more, 100 or more, 1000 or more, etc., individuals. The composite data can then be manipulated, e.g., categorized according to different criteria, and made available to one or more different types of groups, e.g., patient groups, health care practitioner groups, etc., where the manipulation of data may be such as to limit the access of any given group to the type of data that group can access. For example, data can be collected from 100 different individuals that are suffering from the same condition and taking the same medication. The data can be processed and employed to develop easy to follow displays regarding patient compliance with a pharmaceutical dosage regimen and general health. Patient members of the group can access this information and see how their compliance matches with other patient members of the group, and whether they are enjoying the benefits that others are experiencing. In yet another embodiment, doctors can also be granted access to a manipulation of the composite data to see how their patients are matching up with patients of other doctors, and obtain useful information on how real patients respond to a given therapeutic treatment regimen. Additional functionalities can be provided to the groups given access to the composite data, where such functionalities may include, but are not limited to: ability to annotate data, chat functionalities, security privileges, etc.

The inventive pharmacokinetic model allows for drug dosing regimens to be adjusted in real time in response to varying serum levels in the body. The pharmacokinetic model can predict or measure the serum level of a given medication in the body. This data can then be used to calculate when the next dose of medication should be taken by the patient. An alarm can be triggered at that time to alert the patient to take a dose. If the serum level remains high, an alarm can be triggered to alert the patient not to take the next dose at the originally prescribed time interval. The pharmacokinetic model can be used in conjunction with a medication ingestion monitoring system that includes an IEM, such as that described above. Data from this system can be incorporated into the model, as well as population data, measured data, and data input by the patient. Utilizing data from multiple sources, a very powerful and accurate tool can be developed.

In some embodiments, the data gathered by the receiver can be used directly by the pharmacokinetic model to determine when a medication was administered, what medication it was and in what amount. This information can be used to calculate an estimate of the serum level of the medication in the patient. Based on the calculated serum level, the pharmacokinetic model can send an alert to the patient to say either that the serum level is too high and is near or above the toxic level, or that the serum level is too low and they should take another dose. The pharmacokinetic model can be run on the implanted receiver itself or on an external system which receives data from the implanted receiver.

A simple form of the pharmacokinetic model can assume that every patient is the same, and use average population data to model the serum level. A more complex and more accurate model can be obtained by inputting other information about the patient. This information can be inputted by the user, such as a physician, or gathered by the receiver from associated sensors. Information that can be used to adjust the model include other medications being taken, diseases the patient suffers from, patient's organ function, enzyme levels, metabolism, body weight, and age, among other factors. Information can also be inputted by the patient themselves, such as if they feel hypoglycemic, or have pain or dizziness. This can be used as further evidence to validate the predictions of the model.

Examples of food applications include the following. In certain disease conditions, such as diabetes, it can be important what a patient ate and when. In such instances, event markers of the invention are keyed or linked to the type of food a patient eats. For example, one can have a set of event markers for different food items, and one can co-administer them with the food items. From the resultant data, one can do a complete individual metabolic profile on an individual. One knows how many calories the patient is consuming. By obtaining activity and heart rate and ambient temperature versus body temperature data, one can calculate how many calories one is expending. As a result, guidance can be provided to the patient as to what foods to eat and when. Non disease patients may also track food ingestion in this manner. For example, athletes adhering to a strict training diet may employ IEMs to better monitor food ingestion and the effect of the food ingestion on one or more physiological parameters of interest.

As reviewed in the above discussion, IEM systems of the invention find use in both therapeutic and non-therapeutic applications. In therapeutic applications, the IEM may or may not be compounded with a pharmaceutically active agent. In those embodiments where the IEM is compounded with active agent, the resultant compounded composition may be viewed as a pharma-informatics enabled pharmaceutical composition.

In such pharma-informatics embodiments, an effective amount of a composition that includes an IEM and an active agent is administered to a subject in need of the active agent present in the composition, where "effective amount" means a dosage sufficient to produce the desired result, e.g. an improvement in a disease condition or the symptoms associated therewith, the accomplishment of a desired physiological change, etc. The amount that is administered may also be viewed as a therapeutically effective amount. A "therapeutically effective amount" means the amount that, when administered to a subject for treating a disease, is sufficient to effect treatment for that disease.

The composition may be administered to the subject using any convenient means capable of producing the desired

result, where the administration route depends, at least in part, on the particular format of the composition, e.g., as reviewed above. As reviewed above, the compositions can be formatted into a variety of formulations for therapeutic administration, including but not limited to solid, semi solid or liquid, such as tablets, capsules, powders, granules, ointments, solutions, suppositories and injections. As such, administration of the compositions can be achieved in various ways, including, but not limited to: oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracheal, etc., administration. In pharmaceutical dosage forms, a given composition may be administered alone or in combination with other pharmaceutically active compounds, e.g., which may also be compositions having signal generation elements stably associated therewith. In some embodiments, the signal generation element is stably associated with one or more active agents.

The subject methods find use in the treatment of a variety of different conditions, including disease conditions. The specific disease conditions treatable by with the subject compositions are as varied as the types of active agents that can be present in the subject compositions. Thus, disease conditions include, but are not limited to: cardiovascular diseases, cellular proliferative diseases, such as neoplastic diseases, autoimmune diseases, hormonal abnormality diseases, infectious diseases, pain management, and the like.

By treatment is meant at least an amelioration of the symptoms associated with the disease condition afflicting the subject, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the pathological condition being treated. As such, treatment also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g. prevented from happening, or stopped, e.g. terminated, such that the subject no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition. Accordingly, "treating" or "treatment" of a disease includes preventing the disease from occurring in an animal that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease (prophylactic treatment), inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease). For the purposes of this invention, a "disease" includes pain.

In certain embodiments, the subject methods, as described above, are methods of managing a disease condition, e.g., over an extended period of time, such as 1 week or longer, 1 month or longer, 6 months or longer, 1 year or longer, 2 years or longer, 5 years or longer, etc. The subject methods may be employed in conjunction with one or more additional disease management protocols, e.g., electrostimulation based protocols in cardiovascular disease management, such as pacing protocols, cardiac resynchronization protocols, etc; lifestyle, such a diet and/or exercise regimens for a variety of different disease conditions; etc.

In certain embodiments, the methods include modulating a therapeutic regimen based data obtained from the compositions. For example, data may be obtained which includes information about patient compliance with a prescribed therapeutic regimen. This data, with or without additional physiological data, e.g., obtained using one or more sensors, such as the sensor devices described above, may be employed, e.g., with appropriate decision tools as desired, to make determinations of whether a given treatment regimen

should be maintained or modified in some way, e.g., by modification of a medication regimen and/or implant activity regimen. As such, methods of invention include methods in which a therapeutic regimen is modified based on signals obtained from the composition(s).

In certain embodiments, also provided are methods of determining the history of a composition of the invention, where the composition includes an active agent, an identifier element and a pharmaceutically acceptable carrier. In certain embodiments where the identifier emits a signal in response to an interrogation, the identifier is interrogated, e.g., by a wand or other suitable interrogation device, to obtain a signal. The obtained signal is then employed to determine historical information about the composition, e.g., source, chain of custody, etc.

In certain embodiments, a system is employed that is made up of a multiple different IEMs, e.g., 2 or more distinct IEMS, 3 or more distinct IEMS, 4 or more distinct IEMS, etc., including 5 or more, 7 or more, 10 or more distinct IEMS. The distinct IEMs may be configured to provide distinguishable signals, e.g., where the signals may be distinguishable in terms of nature of the signal itself, in terms of timing of emission of the signal, etc. For example, each IEM in such sets may emit a differently coded signal. Alternatively, each IEM may be configured to emit the signal at a different physiological target site, e.g., where each IEM is configured to be activated at a different target physiological site, e.g., where an first IEM is activated in the mouth, a second is activated in the esophagus, a third is activated in the small intestine and a fourth is activated in the large intestine. Such sets of multiple different distinguishable IEMs find use in a variety of different applications. For example, where one has the above described 4 IEM set, one can use the set in a diagnostic application to determine function of the digestive system, e.g., motility through the digestive tract, gastric emptying etc. For example, by noting when each IEM emits its respective signal, a plot of signal time may be generated from which information regarding digestive tract functioning may be obtained.

In another embodiment, one or more IEMs can be configured to be activated at a target site, wherein the target site is reached after a specified period of time. This embodiment can also be used to determine function and motility of the digestive system, e.g. to determine the time it takes to reach various locations of the digestive tract.

The present invention provides the clinician an important new tool in their therapeutic armamentarium: automatic detection and identification of pharmaceutical agents actually delivered into the body. The applications of this new information device and system are multi-fold. Applications include, but are not limited to: (1) monitoring patient compliance with prescribed therapeutic regimens; (2) tailoring therapeutic regimens based on patient compliance; (3) monitoring patient compliance in clinical trials; (4) monitoring usage of controlled substances; and the like. Each of these different illustrative applications is reviewed in greater detail below in copending PCT Application Serial No. PCT/US2006/016370; the disclosure of which is herein incorporated by reference.

Additional applications in which the subject systems find use include those described in U.S. Pat. No. 6,804,558, the disclosure of which is herein incorporated by reference. For example, the subject systems may be used in a medical information communication system which permits monitoring the performance of an implantable medical device (IMD) implanted within a body of a patient, monitoring the health of the patient, and/or remotely delivering a therapy to

the patient through the IMD. A signal receiver of the invention, e.g., in an external format such as a bandaid or implanted format, communicates with the IMD and is capable of bi-directional communication with a communication module, a mobile telephone and/or a Personal Data Assistant (PDA) located outside the patient's body. The system may comprise the IMD, the signal receiver with the communication module and/or a mobile telephone and/or a PDA, a remote computer system, and a communication system capable of bi-directional communication, where the communication module, the mobile telephone and/or the PDA are capable of receiving information from the IMD or relaying information thereto via the signal receiver, which is internal or external to the patient, as reviewed above.

Additional applications in which receivers of the invention may find use include, but are not limited to: fertility monitoring, body fat monitoring, satiety monitoring, satiety control, total blood volume monitoring, cholesterol monitoring, smoking detection, etc.

Kits

Also provided are kits that include one or more in-body devices of the invention. Kits may include one or more in-body devices, e.g., as described above, including ingestible and/or implantable event markers. In those embodiments having a plurality of in-body devices (e.g. ingestible event markers), such may be packaged in a single container, e.g., a single tube, bottle, vial, and the like, or one or more dosage amounts may be individually packaged such that certain kits may have more than one container of an in-body device. In certain embodiments the kits may also include a signal receiving element, or receiver, as reviewed above. In certain embodiments, the kits may also include an external monitor device, e.g., as described above, which may provide for communication with a remote location, e.g., a doctor's office, a central facility etc., which obtains and processes data obtained about the usage of the composition.

The subject kits may also include instructions for how to practice the subject methods using the components of the kit. The instructions may be recorded on a suitable recording medium or substrate. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

Some or all components of the subject kits may be packaged in suitable packaging to maintain sterility. In many embodiments of the subject kits, the components of the kit are packaged in a kit containment element to make a single, easily handled unit, where the kit containment element, e.g., box or analogous structure, may or may not be an airtight container, e.g., to further preserve the sterility of some or all of the components of the kit.

It is to be understood that this invention is not limited to particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and

is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.

All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

It is noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

Certain ranges have been presented herein with numerical values being preceded by the term "about." The term "about" is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this

35

invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.

It is noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future,

36

i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.

What is claimed is:

1. An ingestible event marker, comprising:

a first signal transmission electrode defining a plane;
a second signal transmission electrode defining a plane;
a circuit electrically coupled with the first signal transmission electrode and the second signal

transmission electrode; and

an insulation element defining a center plane substantially parallel to the plane of the first signal transmission electrode and the plane of the second signal transmission electrode, the first signal transmission electrode located on a first side of the center plane, the second signal transmission electrode located on a second side of the center plane different than the first side of the center plane,

the insulation element having a perimeter in the center plane greater than at least one of (1) a perimeter of the first signal transmission electrode in the plane defined by the first signal transmission electrode or (2) a perimeter of the second signal transmission electrode in the plane defined by the second signal transmission electrode,

the first signal transmission electrode and the second signal transmission electrode collectively configured to emit a signal to change a current flowing through an electrically conductive liquid located between the first signal transmission electrode and the second signal transmission electrode based upon an instruction from the circuit.

2. The ingestible event marker according to claim 1, wherein the first signal transmission electrode and the second signal transmission electrode are configured to collectively provide a voltage potential to the circuit when the first signal transmission electrode and the second signal transmission electrode are in contact with the electrically conductive liquid.

3. The ingestible event marker according to claim 1, wherein the insulation element is configured to increase a length of a current path in the electrically conductive liquid between the first signal transmission electrode and the second signal transmission electrode relative to a current path between the first signal transmission electrode and the second signal transmission electrode without the insulation element.

4. The ingestible event marker according to claim 3, wherein the increase in the length of the current path results in an increase in voltage induced in the electrically conductive liquid.

5. The ingestible event marker according to claim 3, wherein the increase in the length of the current path results in providing a signal amplification between the first signal transmission electrode and the second signal transmission electrode.

6. An ingestible event marker, comprising:

a first signal transmission electrode;
a second signal transmission electrode, the second signal transmission electrode positioned a first distance from the first signal transmission electrode;
a circuit electrically coupled with the first signal transmission electrode and the second signal transmission electrode; and

an insulation element intersecting a path (1) between the first signal transmission electrode and the second signal transmission electrode and (2) having the first distance, the first signal transmission electrode and the second signal transmission electrode collectively configured to 5 emit a signal to change a current flowing through an electrically conductive liquid, via a conductive path having a second distance greater than the first distance, located between the first signal transmission electrode and the second signal transmission electrode, based on 10 an instruction from the circuit, the insulation element configured to define a length of the conductive path in the electrically conductive liquid to be greater than the path having the first distance by preventing the current from flowing via the path having 15 the first distance and permitting the current to flow via the conductive path.

7. The ingestible event marker according to claim 6, wherein preventing the current from flowing via the path having the first distance and permitting the current to flow 20 via the conductive path results in an increase in voltage induced in the electrically conductive liquid relative to permitting the current to flow via the path having the first distance.

8. The ingestible event marker according to claim 6, 25 wherein the first signal transmission electrode and the second signal transmission electrode are configured to collectively provide a voltage potential to the circuit when the first signal transmission electrode and the second signal transmission electrode are in contact with the electrically con- 30 ductive liquid.

* * * * *